```
=> d his

     (FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3          47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4          83 S L3
L5          77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6           0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7           0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8             STRUCTURE UPLOADED
L9          50 S L8 SSS SAM
L10       9805 S L8 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11       9054 S L10
L12          0 S L11 AND L5
L13          0 S L11 AND L4
L14          6 S L10 AND CHROMENE
L15        490 S L10 AND KINASE
L16         94 S L10 AND TYROSINE KINASE
               E MUJICA F/AU 25
L17          6 S (E5 OR E6)
               E BUCHHOLZ H/AU 25
L18        148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)
               E CAROLA C/AU 25
L19         37 S (E3 OR E5)
               E RAUTENBERG W/AU 25
L20         49 S (E3 OR E5 OR E7)
               E SURREBBERG C/AU 25
               E SIRRENBERG C/AU 25
L21         33 S (E4)
L22        333 S L16 OR L17 OR L18 OR L19 OR L20 OR L21
L23        131 S L22 AND KINASE
L24         18 S L23 AND CHROM?
L25          0 S L24 AND L4
L26          0 S L23 AND L4

     FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

     FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006
L27       1300 S FLAVANOID?
L28     288351 S KINASE
L29         14 S L27 AND L28
L30      42816 S TYROSINE KINASE
L31          3 S L30 AND L29
L32          2 F STNG
```

```
     FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:55:11 ON 19 DEC 2006

     FILE 'STNGUIDE' ENTERED AT 18:58:47 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:59:14 ON 19 DEC 2006
L33      122622 S OXAL?
L34          20 S L33 AND L16
L35           3 S L33 AND L17
L36          11 S L33 AND L5

     FILE 'STNGUIDE' ENTERED AT 19:00:52 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 19:10:49 ON 19 DEC 2006
L37             STRUCTURE UPLOADED
L38          50 S L37 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 19:11:59 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 19:15:58 ON 19 DEC 2006
L39             STRUCTURE UPLOADED
L40          50 S L39 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 19:17:00 ON 19 DEC 2006

     FILE 'STNGUIDE' ENTERED AT 19:29:06 ON 19 DEC 2006
```

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346v.str



chain nodes :
25 32 48 55 67
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24
26 27 28 29 30 31 35 36 37 38 39 40 42 43 44 45 46 47 49 50 51 52 53 54
57
58 59 60 61 62
chain bonds :
2-42 4-67 23-25 30-32 44-48 53-55
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15
15-16 16-17 19-20 19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-
31
35-36 35-40 36-37 37-38 38-39 39-40 42-43 42-47 43-44 44-45 45-46 46-47 49-50 49-
54
50-51 51-52 52-53 53-54 57-58 57-62 58-59 59-60 60-61 61-62
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-67 42-43 42-47 43-44 44-45 44-48 45-46 46-47
exact bonds :
2-42 23-25 30-32 53-55

```
normalized bonds :
6-7  6-11  7-8  8-9  9-10  10-11  12-13  12-17  13-14  14-15  15-16  16-17  19-20
19-24  20-21  21-22  22-23  23-24  26-27  26-31  27-28  28-29  29-30  30-31  35-36  35-40  36-
37
37-38  38-39  39-40  49-50  49-54  50-51  51-52  52-53  53-54  57-58  57-62  58-59  59-60  60-
61
61-62


G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[*1],[*2],[*3],[
*4],[*5],[*6],[*7]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  19:Atom  20:Atom  21:Atom
22:Atom
23:Atom  24:Atom  25:CLASS  26:Atom  27:Atom  28:Atom  29:Atom  30:Atom  31:Atom  32:CLASS
35:Atom
36:Atom  37:Atom  38:Atom  39:Atom  40:Atom  42:Atom  43:Atom  44:Atom  45:Atom  46:Atom
47:Atom
48:CLASS  49:Atom  50:Atom  51:Atom  52:Atom  53:Atom  54:Atom  55:CLASS  57:Atom  58:Atom
59:Atom
60:Atom  61:Atom  62:Atom  67:CLASS



L1      STRUCTURE UPLOADED

=>  d l1 sss sam
L1 HAS NO ANSWERS
'SSS SAM ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
          data.  (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
          data.
SDA ----- All Structure DAta (image, attributes, connection table and
          map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:.
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:14:52 FILE.'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       87 TO ITERATE

100.0% PROCESSED       87 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1181 TO     2299
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:15:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      1512 TO ITERATE

100.0% PROCESSED     1512 ITERATIONS                          3 ANSWERS
SEARCH TIME: 00.00.01

L3             3 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             167.38     167.59

FILE 'HCAPLUS' ENTERED AT 14:15:15 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006  (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4             1 L3

=> d l4 ibib abs hitstr

L4   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:470326  HCAPLUS  Full-text
DOCUMENT NUMBER:          141:38618
TITLE:                    Preparation of oxadiazolylchromones as modulators of
                          tyrosine kinase signal transduction.
INVENTOR(S):              Mujica-Fernaud, Teresa; Buchholz, Herwig; Carola,
                          Christophe; Rautenberg, Wilfried; Sirrenberg,
                          Christian
PATENT ASSIGNEE(S):       Merck Patent G.m.b.H., Germany
SOURCE:                   Eur. Pat. Appl., 33 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1426372	A1	20040609	EP 2003-26103	20031113
EP 1426372	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10256182	A1	20040624	DE 2002-10256182	20021202
AT 315564	T	20060215	AT 2003-26103	20031113
ES 2255654	T3	20060701	ES 2003-3026103	20031113
US 2004138464	A1	20040715	US 2003-725346	20031202
PRIORITY APPLN. INFO.:			DE 2002-10256182 A	20021202
OTHER SOURCE(S):	MARPAT 141:38618			

GI



I

AB Title compds. [I; R = A, pyridyl, (substituted) Ph; X = H, OH, PhO, OA, O2CA, SO3H, OSO3H, OSO3A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2, etc.; A = alkyl, fluoroalkyl; n = 1-4], were prepared Thus, 2,5-dihydroxyacetophenone and di-Et oxalate were heated 3 h at 80° in EtOH to give 6-hydroxy-2-ethoxycarbonylchromone. This was refluxed with aqueous HCl in HOAc to give 6-hydroxychromon-2-carboxylic acid. The latter in THF at -10° was treated with Et3N and iso-Bu chloroformate; after stirring for 1 h, 4-tert-butylbenzaldoxime in THF was added followed by stirring for 30 min. at room temperature and at reflux for 90 min. to give 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5- yl]chromone. The latter inhibited Tie2 receptor tyrosine kinase with IC50 >10 μM.

IT 700813-20-3P, 6-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-21-4P, 7-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-22-5P, 6-Hydroxy-2-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]chromone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction)

RN 700813-20-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-6-hydroxy- (9CI) (CA INDEX NAME)



RN 700813-21-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-7-hydroxy- (9CI) (CA INDEX NAME)



RN 700813-22-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-hydroxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)



=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.64	175.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'STNGUIDE' ENTERED AT 14:16:05 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=> d his

(FILE 'HOME' ENTERED AT 14:13:50 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 14:13:57 ON 19 DEC 2006
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 3 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:15:15 ON 19 DEC 2006
L4 1 S L3

FILE 'STNGUIDE' ENTERED AT 14:16:05 ON 19 DEC 2006

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST	0.06	175.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 14:16:19 ON 19 DEC 2006

Connecting via Winsock to STN

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346vi.str







chain nodes :
25 32 48 55 67
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24
26 27 28 29 30 31 35 36 37 38 39 40 42 43 44 45 46 47 49 50 51 52 53 54
57
58 59 60 61 62
chain bonds :
4-67 23-25 30-32 44-48 53-55
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15
15-16 16-17 19-20 19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-
31
35-36 35-40 36-37 37-38 38-39 39-40 42-47 42-43 43-44 44-45 45-46 46-47 49-50 49-
54
50-51 51-52 52-53 53-54 57-58 57-62 58-59 59-60 60-61 61-62
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-67 23-25 30-32 42-47 42-43 43-44 44-45 44-48 45-46
46-47 53-55
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 19-20
19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31 35-36 35-40 36-

```
37
37-38  38-39  39-40  49-50  49-54  50-51  51-52  52-53  53-54  57-58  57-62  58-59  59-60  60-
61
61-62


G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[*1],[*2],[*3],[
*4],[*5],[*6],[*7]

G2:O,S

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  19:Atom  20:Atom  21:Atom
22:Atom
23:Atom  24:Atom  25:CLASS  26:Atom  27:Atom  28:Atom  29:Atom  30:Atom  31:Atom  32:CLASS
35:Atom
36:Atom  37:Atom  38:Atom  39:Atom  40:Atom  42:Atom  43:Atom  44:Atom  45:Atom  46:Atom
47:Atom
48:CLASS  49:Atom  50:Atom  51:Atom  52:Atom  53:Atom  54:Atom  55:CLASS  57:Atom  58:Atom
59:Atom
60:Atom  61:Atom  62:Atom  67:CLASS  68:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:22:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       62 TO ITERATE

100.0% PROCESSED       62 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          768 TO     1712
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l2 sss full
FULL SEARCH INITIATED 14:22:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1078 TO ITERATE

100.0% PROCESSED     1078 ITERATIONS                                 12 ANSWERS
SEARCH TIME: 00.00.01

L3           12 SEA SSS FUL L1

=> d scan

L3   12 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-,
     2,3,4,6-tetrabenzoate, (1R)- (9CI)
MF   C42 H31 N3 O12
```

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):12

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)- (9CI)
MF C14 H14 N2 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (9CI)
MF C43 H34 N2 O11

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (9CI)
MF C14 H15 N3 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-7-hydroxy- (9CI)
MF C21 H18 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (9CI)
MF C15 H18 N2 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]- (9CI)
MF C14 H13 N3 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, 2,3,4,6-tetrabenzoate, (1R)- (9CI)
MF C42 H32 N2 O10

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]- (9CI)
MF C15 H16 N2 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-4-one, 6-hydroxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-(9CI)
MF C16 H9 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, (1R)- (9CI)
MF C14 H16 N2 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-6-hydroxy- (9CI)
MF C21 H18 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	167.59

FILE 'HCAPLUS' ENTERED AT 14:22:58 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:21:32 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 14:21:39 ON 19 DEC 2006
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 12 S L2 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:22:58 ON 19 DEC 2006

=> s l3
L4 2 L3

=> d l4 ti

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
TI 1,3-Dipolar cycloaddition reactions on carbohydrate-based templates: Synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhibitors

=> d l4 ti 2

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.

=> d l4 1 ibib abs hitstr

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:757596 HCAPLUS Full-text
DOCUMENT NUMBER: 145:315180
TITLE: 1,3-Dipolar cycloaddition reactions on carbohydrate-based templates: Synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhibitors
AUTHOR(S): Benltifa, Mahmoud; Vidal, Sebastien; Gueyrard, David; Goekjian, Peter G.; Msaddek, Moncef; Praly, Jean-Pierre
CORPORATE SOURCE: Laboratoire de Chimie Organique 2 - Glycochimie, UMR-CNRS 5181, CPE-Lyon, Universite Claude Bernard Lyon 1, Villeurbanne, F-69622, Fr.
SOURCE: Tetrahedron Letters (2006), 47(34), 6143-6147
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:315180
AB 1,3-Dipolar cycloaddn. of aryl nitrile oxides to benzyl/acetyl-protected exo-glucals and to a benzoylated glucosyl cyanide led in high yield to spiro-isoxazolines and to 3-aryl-5-glucosyl-1,2,4-oxadiazoles, resp. The choice of the protective groups was important to the outcome of the cycloaddn. and for the deprotection of the adducts. Cleavage of the ester protecting groups (acetyl, benzoyl) provided water-soluble spiro-isoxazolines and 3-aryl-5-glucosyl-1,2,4-oxadiazoles, evaluated as glycogen phosphorylase inhibitors. Preliminary tests showed IC50 values in the μM range.
IT 909109-15-5P 909109-16-6P 909109-17-7P
RL: BYP (Byproduct); PREP (Preparation)
(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)
RN 909109-15-5 HCAPLUS
CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 909109-16-6 HCAPLUS
CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 909109-17-7 HCAPLUS
CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-13-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)
RN 909109-13-3 HCAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-09-7P 909109-10-0P 909109-11-1P
RL: RCT (Reactant); SPN (Synthetiç preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)
RN 909109-09-7 HCAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 909109-10-0 HCAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, 2,3,4,6-tetrabenzoate, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 909109-11-1 HCAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-12-2P 909109-14-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)
RN 909109-12-2 HCAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 909109-14-4 HCAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.83	178.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'STNGUIDE' ENTERED AT 14:23:58 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	178.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'REGISTRY' ENTERED AT 14:26:45 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346vii.str





chain nodes :
12
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
8-12
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 8-12 9-10 10-11

G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 15:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5 sss sam
SAMPLE SEARCH INITIATED 14:27:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      376 TO ITERATE

100.0% PROCESSED      376 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         6357 TO     8683
PROJECTED ANSWERS:               0 TO        0

L6             0 SEA SSS SAM L5

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44     179.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.75

STN INTERNATIONAL LOGOFF AT 14:27:27 ON 19 DEC 2006
```

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346viii.str



chain nodes :
11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
8-12 10-11 12-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
5-7 6-10 7-8 8-9 9-10 10-11 12-13
exact bonds :
8-12 12-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:53:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       39 TO ITERATE

100.0% PROCESSED     39 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          406 TO     1154
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> fil stng
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.88       1.09

FILE 'STNGUIDE' ENTERED AT 16:54:27 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE
```

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346ix.str



chain nodes :
11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
8-12 10-11 12-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
5-7 6-10 7-8 8-9 9-10 10-11 12-13
exact bonds :
8-12 12-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 17:32:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       19 TO ITERATE

100.0% PROCESSED       19 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          119 TO      641
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> fil stng
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44       0.65

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> s l1 sss full
SUBSTANCE QUERIES NOT VALID IN THIS FILE
The logic expression entered contains L#s or saved query names which
correspond to structures built by the STRUCTURE command or to screen
sets.  These must be searched in a substance file such as the REGISTRY
file.  In some files you may use a Registry Number answer set from a
structure search as a search term or profile in some bibliographic
file containing Registry Numbers, e.g.  the CA file.  For an
explanation, enter "HELP CROSSOVER" at an arrow prompt (=>).

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.12       0.77

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 DEC 2006  HIGHEST RN 915867-78-6
DICTIONARY FILE UPDATES:  18 DEC 2006  HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l1 sss full
FULL SEARCH INITIATED 17:33:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 291 TO ITERATE

100.0% PROCESSED 291 ITERATIONS 47 ANSWERS
SEARCH TIME: 00.00.01

L3 47 SEA SSS FUL L1

=> d scan

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo-5-(2-phenoxyethoxy)- (9CI)
MF C18 H13 Cl O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 5-hydroxy-4-oxo- (9CI)
MF C10 H5 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride, 5-hydroxy-4,10-dioxo-6-(2-propenyl)- (9CI)
MF C17 H8 Cl2 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-fluoro-4-oxo- (9CI)
MF C10 H4 Cl F O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-methoxy-4-oxo- (9CI)
MF C11 H7 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-6-acrylic acid, 2-(chloroformyl)-5-hydroxy-β-methyl-4-oxo-, δ-lactone (7CI)
MF C14 H7 Cl O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 8-(aminocarbonyl)-7-hydroxy-4-oxo- (9CI)
MF C11 H6 Cl N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6,7-dihydroxy-4-oxo- (9CI)
MF C10 H5 Cl O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-nitro-4-oxo- (9CI)
MF C10 H4 Cl N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo- (9CI)
MF C23 H14 Cl2 O9



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-ethoxy-8-(4-methyl-1-piperazinyl)-4-oxo- (9CI)
MF C17 H19 Cl N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-chloro-4-oxo- (8CI, 9CI)
MF C10 H4 Cl2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride, 5-methoxy-4,10-dioxo- (9CI)
MF C15 H6 Cl2 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride, 6-bromo-5-hydroxy-4,10-dioxo- (9CI)
MF C14 H3 Br Cl2 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4H-1-Benzopyran-2-carbonyl chloride, 5-(2-ethoxyethoxy)-4-oxo- (9CI)
MF C14 H13 Cl O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-bromo-4-oxo- (9CI)
MF C10 H4 Br Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 3-methyl-4-oxo- (9CI)
MF C11 H7 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 9H-Furo[2,3-f][1]benzopyran-7-carbonyl chloride, 3-methyl-9-oxo- (7CI)
MF C13 H7 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-14C-2-carbonyl-14C chloride, 4-oxo- (9CI)
MF C10 H5 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6,7-bis(acetyloxy)-4-oxo- (9CI)
MF C14 H9 Cl O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-fluoro-4-oxo- (9CI)
MF C10 H4 Cl F O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-(1,1-dimethylethyl)-8-nitro-4-oxo- (9CI)
MF C14 H12 Cl N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo-, 4-chlorocoumarin (6CI)
MF C10 H5 Cl O3 . C9 H5 Cl O2

CM 1



CM 2



L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6,8-bis(1,1-dimethylethyl)-4-oxo- (9CI)
MF C18 H21 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[[2-(formyloxy)-1,3-propanediyl]bis(oxy)]bis[4-oxo- (9CI)
MF C24 H14 Cl2 O10



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride, 4,10-dioxo-5-(2-propenyloxy)- (9CI)
MF C17 H8 Cl2 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Naphtho[2,3-b]pyran-2-carbonyl chloride, 6,7,8,9-tetrahydro-4-oxo-10-propyl- (9CI)
MF C17 H17 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-nitro-4-oxo- (9CI)
MF C10 H4 Cl N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Pyrano[3,2-g]quinoline-2,8-dicarbonyl dichloride, 6-chloro-4-oxo-10-propyl- (9CI)
MF C17 H10 Cl3 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2,7-dicarbonyl dichloride, 4-oxo- (9CI)
MF C11 H4 Cl2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 3-bromo-4-oxo- (9CI)
MF C10 H4 Br Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy- (9CI)
MF C17 H12 Cl N O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-chloro-4-oxo- (9CI)
MF C10 H4 Cl2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 3-methyl-4-oxo-8-(1-propenyl)- (9CI)
MF C14 H11 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI)
MF C10 H5 Cl O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 5-(3-methylbutoxy)-4-oxo-8-(2-propenyl)- (9CI)
MF C18 H19 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Naphtho[2,3-b]pyran-2-carbonyl chloride, 6,7,8,9-tetrahydro-4-oxo- (9CI)
MF C14 H11 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H,6H-Benzo[1,2-b:5,4-b']dipyran-2,8-dicarbonyl dichloride, 10-ethyl-4,6-dioxo- (9CI)
MF C16 H8 Cl2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Naphtho[2,3-b]pyran-2-carbonyl chloride, 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl- (9CI)
MF C17 H17 Cl O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-methyl-4-oxo- (9CI)
MF C11 H7 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-methyl-3-octyl-4-oxo- (9CI)
MF C19 H23 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2,8-dicarbonyl dichloride, 6-methyl-4-oxo- (9CI)
MF C12 H6 Cl2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Pyrano[3,2-g]quinoline-2,8-dicarbonyl dichloride, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- (9CI)
MF C19 H15 Cl2 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 3-chloro-4-oxo- (9CI)
MF C10 H4 Cl2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-bromo-4-oxo- (9CI)
MF C10 H4 Br Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 7-methyl-4-oxo- (9CI)
MF C11 H7 Cl O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-1-Benzopyran-2-carbonyl chloride, 6,8-dichloro-4-oxo- (8CI)
MF C10 H3 Cl3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

```
     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3           47 S L1 SSS FULL

=> fil hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       166.94     167.71

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006  (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4           83 L3

=> S L4 AND 1800<=PY<=2001
      21842532 1800<=PY<=2001
L5           77 L4 AND 1800<=PY<=2001

=> fil stng
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         5.06     172.77

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> d his

     (FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1               STRUCTURE UPLOADED
L2             0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3           47 S L1 SSS FULL
```

```
     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4            83 S L3
L5            77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

=> fil hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.90      173.67

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006  (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l5 and ( 4H-1-Benzopyran-2-carbonyl chloride methyl oxo)
         39560 4H
       8939125 1
         12178 BENZOPYRAN
          1131 BENZOPYRANS
         12576 BENZOPYRAN
                 (BENZOPYRAN OR BENZOPYRANS)
       8979331 2
        171562 CARBONYL
         27462 CARBONYLS
        179753 CARBONYL
                 (CARBONYL OR CARBONYLS)
       1107475 CHLORIDE
        159773 CHLORIDES
       1180706 CHLORIDE
                 (CHLORIDE OR CHLORIDES)
        988977 METHYL
           668 METHYLS
        989384 METHYL
                 (METHYL OR METHYLS)
        927662 ME
         10527 MES
        934211 ME
                 (ME OR MES)
       1587567 METHYL
                 (METHYL OR ME)
        154530 OXO
            26 OXOS
        154533 OXO
                 (OXO OR OXOS)
             0 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO
```

```
                (4H(W)1(W)BENZOPYRAN(W)2(W)CARBONYL(W)CHLORIDE(W)METHYL(W)OXO)
L6            0 L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)

=> s l5 and (carbonyl chloride methyl oxo)
        171562 CARBONYL
         27462 CARBONYLS
        179753 CARBONYL
                  (CARBONYL OR CARBONYLS)
       1107475 CHLORIDE
        159773 CHLORIDES
       1180706 CHLORIDE
                  (CHLORIDE OR CHLORIDES)
        988977 METHYL
           668 METHYLS
        989384 METHYL
                  (METHYL OR METHYLS)
        927662 ME
         10527 MES
        934211 ME
                  (ME OR MES)
       1587567 METHYL
                  (METHYL OR ME)
        154530 OXO
            26 OXOS
        154533 OXO
                  (OXO OR OXOS)
             0 CARBONYL CHLORIDE METHYL OXO
                  (CARBONYL(W)CHLORIDE(W)METHYL(W)OXO)
L7            0 L5 AND (CARBONYL CHLORIDE METHYL OXO)

=> fil stng
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         5.06      178.73

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=>
=> d his

     (FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1                STRUCTURE UPLOADED
L2             0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3            47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4            83 S L3
L5            77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6             0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7             0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)
```

```
     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006  (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l10
L11       9054 L10

=> d his

     (FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1               STRUCTURE UPLOADED
L2             0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3            47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4            83 S L3
L5            77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6             0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7             0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8               STRUCTURE UPLOADED
```

```
L9            50 S L8 SSS SAM
L10         9805 S L8 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11         9054 S L10

=> s l11 and l5
L12           0 L11 AND L5

=> s l11 and l4
L13           0 L11 AND L4

=> s l10 and chromene
           9054 L10
           1962 CHROMENE
            885 CHROMENES
           2270 CHROMENE
                (CHROMENE OR CHROMENES)
L14           6 L10 AND CHROMENE

=> d l14 ibib abs hitstr

L14  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:931479  HCAPLUS  Full-text
DOCUMENT NUMBER:          140:5049
TITLE:                    Preparation of substituted 4-aryl-4H-pyrrolo[2,3-h]
                          chromenes and analogs as activators of
                          caspases and inducers of apoptosis and their uses
                          against cancer and other disorders
INVENTOR(S):              Cai, Sui Xiong; Jiang, Songchun; Kemnitzer, William
                          E.; Zhang, Hong; Attardo, Giorgio; Denis, Real
PATENT ASSIGNEE(S):       Cytovia, Inc., USA; Shire Biochem, Inc.
SOURCE:                   PCT Int. Appl., 110 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    ---------------------    --------
     WO 2003097806         A2    20031127    WO 2003-US15427          20030516
     WO 2003097806         A3    20040930
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2484702            A1    20031127    CA 2003-2484702          20030516
     AU 2003230411         A1    20031202    AU 2003-230411           20030516
     EP 1509515            A2    20050302    EP 2003-724599           20030516
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1668609            A     20050914    CN 2003-816725           20030516
     JP 2005531566         T     20051020    JP 2004-506465           20030516
     US 2006104998         A1    20060518    US 2004-514427           20041116
PRIORITY APPLN. INFO.:                       US 2002-378079P     P    20020516
                                             WO 2003-US15427     W    20030516

OTHER SOURCE(S):          MARPAT 140:5049
GI
```



I



II

AB The present invention is directed to substituted 4-aryl-4H-pyrrolo[2,3-h] chromenes and analogs thereof (shown as I; variables defined below; e.g. II). The present invention also relates to the discovery that compds. I are activators of caspases and inducers of apoptosis. Therefore, I can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. The ability to activate the caspase cascade and induce apoptosis in human breast cancer cell lines T-47D and ZR-75-1 was measured for .apprx.50 examples of I, e.g. EC50 (nM) = 2.3 and 1.6, resp., for II. Although the methods of preparation are not claimed, .apprx.50 example prepns. are included. For I: R1 = alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, aminoalkyl and oxiranylalkyl; R3 and R4 = H, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C1-10 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthio; R5 is H or C1-10 alkyl. A is (un)substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; D is (un)substituted and is a heteroarom., partially saturated (un)saturated heterocyclic fused ring, wherein said fused ring has 5 or 6 ring atoms, wherein one or two of said ring atoms are N atoms and the others of said ring atoms are C atoms. Y is CN, COR19, CO2R19 or CONR20R21, wherein R19, R20 and R21 = H, C1-10-alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R20 and R21 are taken together with the N to form a heterocycle; and Z is NR22R23, NHCOR22N(COR23)2, N(COR22)(COR23), N:CHOR19 or N:CHR19 wherein R22 and R23 = H, C1-4 alkyl or aryl, or R22 and R23 are combined together with the group attached to them to form a heterocycle.

IT 127-07-1, Hydroxyurea
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of substituted 4-aryl-4H-pyrrolo[2,3-h] chromenes and analogs as activators of caspases and inducers of apoptosis and their uses against cancer and other disorders)

RN 127-07-1 HCAPLUS

CN Urea, hydroxy- (6CI, 8CI, 9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

```
L2            0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3           47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4           83 S L3
L5           77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6            0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7            0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8              STRUCTURE UPLOADED
L9           50 S L8 SSS SAM
L10        9805 S L8 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11         9054 S L10
L12            0 S L11 AND L5
L13            0 S L11 AND L4
L14            6 S L10 AND CHROMENE

=> s l10 and kinase
          9054 L10
        279466 KINASE
         54347 KINASES
        288351 KINASE
                 (KINASE OR KINASES)
L15        490 L10 AND KINASE

=> s l10 and tyrosine kinase
          9054 L10
        155428 TYROSINE
          2627 TYROSINES
        155960 TYROSINE
                 (TYROSINE OR TYROSINES)
        279466 KINASE
         54347 KINASES
        288351 KINASE
                 (KINASE OR KINASES)
         42816 TYROSINE KINASE
                 (TYROSINE(W)KINASE)
L16         94 L10 AND TYROSINE KINASE

=> E MUJICA F/AU 25
E1           2     MUJICA E/AU
E2           2     MUJICA EMILIA/AU
E3           0 --> MUJICA F/AU
E4           1     MUJICA FELIX DIAZ/AU
E5           1     MUJICA FERNAUD M TERESA/AU
E6           5     MUJICA FERNAUD TERESA/AU
E7           4     MUJICA G/AU
E8           1     MUJICA G AYESTARAN/AU
E9           1     MUJICA GONZALEZ MANUEL/AU
E10          1     MUJICA GUSTAVO ROJAS/AU
E11          2     MUJICA HECTOR J/AU
E12          1     MUJICA IGNACIO/AU
E13          2     MUJICA J D/AU
```

```
E14           1      MUJICA J L/AU
E15           3      MUJICA JIMENEZ C/AU
E16          11      MUJICA JIMENEZ CARLOS/AU
E17           1      MUJICA JOSE L/AU
E18           1      MUJICA L E/AU
E19           1      MUJICA L F/AU
E20           2      MUJICA LOPEZ K I/AU
E21           2      MUJICA LORENA/AU
E22           4      MUJICA M B/AU
E23           3      MUJICA M T/AU
E24           6      MUJICA M TERESA/AU
E25           1      MUJICA MARIA C/AU

=> S (E5 OR E6)
              1 "MUJICA FERNAUD M TERESA"/AU
              5 "MUJICA FERNAUD TERESA"/AU
L17           6 ("MUJICA FERNAUD M TERESA"/AU OR "MUJICA FERNAUD TERESA"/AU)

=> E BUCHHOLZ H/AU 25
E1            3      BUCHHOLZ GUNTHER/AU
E2            2      BUCHHOLZ GUSTAV/AU
E3           56 --> BUCHHOLZ H/AU
E4            3      BUCHHOLZ H G/AU
E5            1      BUCHHOLZ H V/AU
E6            1      BUCHHOLZ H W/AU
E7            2      BUCHHOLZ HAGEN/AU
E8           12      BUCHHOLZ HANS GEORG/AU
E9            4      BUCHHOLZ HANS VOLKER/AU
E10           2      BUCHHOLZ HARTMUT/AU
E11           1      BUCHHOLZ HEIKE/AU
E12          10      BUCHHOLZ HEINRICH/AU
E13           3      BUCHHOLZ HEINZ/AU
E14           2      BUCHHOLZ HELENE/AU
E15           1      BUCHHOLZ HERBERT/AU
E16           1      BUCHHOLZ HERBERT F/AU
E17           1      BUCHHOLZ HERMANN/AU
E18           1      BUCHHOLZ HERTHA NEE MEISENHEIMER/AU
E19          74      BUCHHOLZ HERWIG/AU
E20          12      BUCHHOLZ HERWIG A/AU
E21           1      BUCHHOLZ HERWING/AU
E22          17      BUCHHOLZ HORST/AU
E23           1      BUCHHOLZ HORZT/AU
E24           2      BUCHHOLZ HUGO/AU
E25           5      BUCHHOLZ I/AU

=> S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)
             56 "BUCHHOLZ H"/AU
              3 "BUCHHOLZ H G"/AU
              1 "BUCHHOLZ H V"/AU
              1 "BUCHHOLZ H W"/AU
             74 "BUCHHOLZ HERWIG"/AU
             12 "BUCHHOLZ HERWIG A"/AU
              1 "BUCHHOLZ HERWING"/AU
L18         148 ("BUCHHOLZ H"/AU OR "BUCHHOLZ H G"/AU OR "BUCHHOLZ H V"/AU OR "BUCHHOLZ H W"/AU
OR "BUCHHOLZ HERWIG"/AU OR "BUCHHOLZ HERWIG A"/AU OR "BUCHHOLZ HERWING"/AU)

=> E CAROLA C/AU 25
E1            1      CAROLA ANTONIETTA/AU
E2            1      CAROLA ARMAND/AU
E3           13 --> CAROLA C/AU
E4           16      CAROLA CESARE/AU
E5           24      CAROLA CHRISTOPHE/AU
E6            6      CAROLA E/AU
E7            6      CAROLA ELISABETH/AU
E8            1      CAROLA EVA/AU
E9            1      CAROLA F/AU
```

```
E10           1      CAROLA FINARELLI ALBA/AU
E11           1      CAROLA JOSEPH M/AU
E12           1      CAROLA KIM V/AU
E13           1      CAROLA LANDER/AU
E14           1      CAROLA M/AU
E15           1      CAROLA MARIA/AU
E16           7      CAROLA T P G/AU
E17           1      CAROLA V/AU
E18           1      CAROLA VILLANUEVA C/AU
E19           2      CAROLAN ADRIAN/AU
E20           1      CAROLAN B M/AU
E21           5      CAROLAN C/AU
E22           1      CAROLAN C A/AU
E23           3      CAROLAN CATHERINE/AU
E24           1      CAROLAN CHRISTINA/AU
E25           1      CAROLAN D/AU

=> S (E3 OR E5)
             13 "CAROLA C"/AU
             24 "CAROLA CHRISTOPHE"/AU
L19          37 ("CAROLA C"/AU OR "CAROLA CHRISTOPHE"/AU)

=> E RAUTENBERG W/AU 25
E1            2      RAUTENBERG U/AU
E2            2      RAUTENBERG UTE/AU
E3           16 --> RAUTENBERG W/AU
E4            3      RAUTENBERG WERNER/AU
E5           32      RAUTENBERG WILFRIED/AU
E6            2      RAUTENBERGER RALF/AU
E7            1      RAUTENBERGER WILFRIED/AU
E8            5      RAUTENBURG H W/AU
E9            1      RAUTENBURG P/AU
E10           1      RAUTENBUSCH W/AU
E11           1      RAUTENFELDT V/AU
E12           1      RAUTENGARTEN A M/AU
E13           2      RAUTENGARTEN CARSTEN/AU
E14           1      RAUTENGARTEN JENS/AU
E15           4      RAUTENHAUS HEINRICH/AU
E16           1      RAUTENKRANZ ANDREAS A F/AU
E17           1      RAUTENKRANZ D/AU
E18           1      RAUTENKRANZ DOUG/AU
E19           3      RAUTENSCHLEIN M/AU
E20           1      RAUTENSCHLEIN MARTINA/AU
E21           3      RAUTENSCHLEIN S/AU
E22           8      RAUTENSCHLEIN SILKE/AU
E23           1      RAUTENSHTEIN E I/AU
E24           1      RAUTENSHTEIN S M/AU
E25           2      RAUTENSHTEIN V YA/AU

=> S (E3 OR E5 OR E7)
             16 "RAUTENBERG W"/AU
             32 "RAUTENBERG WILFRIED"/AU
              1 "RAUTENBERGER WILFRIED"/AU
L20          49 ("RAUTENBERG W"/AU OR "RAUTENBERG WILFRIED"/AU OR "RAUTENBERGER WILFRIED"/AU)

=> E SURREBBERG C/AU 25
E1            2      SURRE L/AU
E2            1      SURRE MICHELE/AU
E3            0 --> SURREBBERG C/AU
E4            2      SURREL FANNY/AU
E5            1      SURREL MARIE NOELLE/AU
E6            5      SURREL Y/AU
E7            4      SURREL YVES/AU
E8            2      SURRENA HARLAND J/AU
E9            1      SURRENA P S/AU
E10           1      SURRENDRANATH V/AU
```

```
E11          34      SURRENTI C/AU
E12          39      SURRENTI CALOGERO/AU
E13           3      SURRENTI E/AU
E14           4      SURRENTI ELISABETTA/AU
E15           2      SURRENTI NADIA/AU
E16           3      SURRENTINO S/AU
E17           1      SURRENTINO SANDRO/AU
E18           1      SURRETT A D/AU
E19           2      SURRETT APRIL D/AU
E20           2      SURRETT R S/AU
E21           1      SURRETTE J/AU
E22          12      SURREY A R/AU
E23         122      SURREY ALEXANDER R/AU
E24           1      SURREY ALEXANDER ROBERT/AU
E25           2      SURREY ALLAN/AU

=> E SIRRENBERG C/AU 25
E1            1      SIRRENBERG A/AU
E2            1      SIRRENBERG ANKE/AU
E3            0 --> SIRRENBERG C/AU
E4           33      SIRRENBERG CHRISTIAN/AU
E5            2      SIRRENBERG S/AU
E6            3      SIRRENBERG W/AU
E7            1      SIRRENBERG WALTER/AU
E8            9      SIRRENBERG WALTHER/AU
E9           75      SIRRENBERG WILHELM/AU
E10           1      SIRRETT D/AU
E11           1      SIRRETTA RAYMOND/AU
E12           2      SIRRETTA RAYMOND J/AU
E13           1      SIRRI A/AU
E14           5      SIRRI ALESSANDRA/AU
E15           1      SIRRI CAM F/AU
E16           1      SIRRI CLOTILDE S/AU
E17           9      SIRRI F/AU
E18          43      SIRRI G/AU
E19           1      SIRRI KES SULEYMAN/AU
E20           1      SIRRI KILIC S/AU
E21           1      SIRRI M/AU
E22           4      SIRRI V/AU
E23          13      SIRRI VALENTINA/AU
E24           4      SIRRIDGE MARJORIE S/AU
E25           1      SIRRINE F A/AU

=> S (E4)
L21          33 ("SIRRENBERG CHRISTIAN"/AU)

=> d his

     (FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1                STRUCTURE UPLOADED
L2             0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3            47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4            83 S L3
L5            77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
```

```
L6            0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7            0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8              STRUCTURE UPLOADED
L9             50 S L8 SSS SAM
L10          9805 S L8 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11          9054 S L10
L12             0 S L11 AND L5
L13             0 S L11 AND L4
L14             6 S L10 AND CHROMENE
L15           490 S L10 AND KINASE
L16            94 S L10 AND TYROSINE KINASE
                  E MUJICA F/AU 25
L17             6 S (E5 OR E6)
                  E BUCHHOLZ H/AU 25
L18           148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)
                  E CAROLA C/AU 25
L19            37 S (E3 OR E5)
                  E RAUTENBERG W/AU 25
L20            49 S (E3 OR E5 OR E7)
                  E SURREBBERG C/AU 25
                  E SIRRENBERG C/AU 25
L21            33 S (E4)

=> s l16 or l17 or l18 or l19 or l20 or l21
L22          333 L16 OR L17 OR L18 OR L19 OR L20 OR L21

=> s l22 and kinase
         279466 KINASE
          54347 KINASES
         288351 KINASE
                  (KINASE OR KINASES)
L23          131 L22 AND KINASE

=> s l23 and chrom?
        1576479 CHROM?
L24           18 L23 AND CHROM?

=> s l24 and l4
L25            0 L24 AND L4

=> s l23 and l4
L26            0 L23 AND L4

=> d l24 ibib abs

L24  ANSWER 1 OF 18  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:1117612  HCAPLUS  Full-text
DOCUMENT NUMBER:         145:460599
TITLE:                   Resorbable implants prepared from a metal base and
                         polymer coating with drugs
INVENTOR(S):             Orlowski, Michael
PATENT ASSIGNEE(S):      Germany
SOURCE:                  Ger. Offen., 12pp.
                         CODEN: GWXXBX
DOCUMENT TYPE:           Patent
LANGUAGE:                German
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

DE 102005018356	A1	20061026	DE 2005-102005018356	20050420
PRIORITY APPLN. INFO.:			DE 2005-102005018356	20050420

AB The invention concerns resorbable implants that are prepared from metals, or metal alloys and coated with biodegradable polymers that include active substances, e.g. anticancer drugs, antiinflammatory agents, antiphlogistics, cytotoxic, antithrombotic agents, corticoids, sex hormones, statins, epothilone, prostacyclins, or angiogenesis inductors. Stents for blood vessels, urinary tract, respiratory tract, bile duct, and gastrointestinal tract can be prepared Thus a stent was prepared from (weight/weight): zinc 90; magnesium 6; calcium 1; yttrium 2; other metals, salts, nonmetals, carbon, sulfur, oxygen, nitrogen, and(or) hydrogen 1. The stent was dip-coated with a solution of a polyglycol with doxorubicin.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 124 ibib abs 2-18

L24 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:909276 HCAPLUS Full-text
DOCUMENT NUMBER: 145:328345
TITLE: Application of compound proteasome inhibitor PSI in preparation of medicine for cure of m2 acute myeloid leukemia and chronic myeloid leukemia
INVENTOR(S): Zhou, Guangbiao; Liu, Dapeng; Hu, Zheng
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1824288	A	20060830	CN 2005-10102194	20051209
PRIORITY APPLN. INFO.:			CN 2005-10102194	20051209

AB This invention relates to application of compound proteasome inhibitor (PSI) in preparation of medicine for cure of t(8;21) chromosome ectopic M2 acute myeloid leukemia and chronic myeloid leukemia. Title compound PSI is used with cytarabine, daunorubicin, idarubicin, granulocyte colony stimulating factor or granulocyte monocyte colony stimulating factor to cure of M2 acute myeloid leukemia. Title compound PSI is used with cytarabine, hydroxyurea, interferon, or protein tyrosine kinase inhibitor STI-571 to cure of chronic myeloid leukemia.

L24 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:381897 HCAPLUS Full-text
DOCUMENT NUMBER: 145:486710
TITLE: Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance
AUTHOR(S): Underhill-Day, N.; Pierce, A.; Thompson, S. E.; Xenaki, D.; Whetton, A. D.; Owen-Lynch, P. J.
CORPORATE SOURCE: Faculty of Life Sciences, Christie Hospital, University of Manchester, Withington, Manchester, UK
SOURCE: British Journal of Haematology (2006), 132(6), 774-783
CODEN: BJHEAL; ISSN: 0007-1048
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Philadelphia chromosome-pos., chronic myeloid leukemia (CML) stem and progenitor cells have a survival and growth advantage compared with their normal counterparts. The mechanisms through which the BCR/ABL protein tyrosine kinase (PTK) induces these effects and the important domains within this protein are not fully defined. The F- and G-actin binding region of the BCR/ABL C-terminus may be important in BCR/ABL-mediated events, and we have investigated this by expressing a C-terminus deletion mutant of the temperature-

sensitive BCR/ABL PTK, in a haemopoietic progenitor cell line, which models the chronic phase of CML. The truncated BCR/ABL PTK displayed similar levels of PTK activity when compared with wild type and activation of second messenger formation (in the form of sn-1,2-diacylglycerol) remains intact. On fibronectin substrata, localization of the protein to the periphery of the cell was, however, dependent on the C-terminus of BCR/ABI PTK. Deletion of the C-terminus reversed both BCR/ABL-mediated apoptotic suppression anc drug resistance although the progenitor cells did retain a proliferative advantage at lov concns. of growth factor. These results demonstrated that the C-terminal actin-binding domain of BCR/ABL is important for some of BCR/ABL PTK-mediated leukemogenic effects.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:167588 HCAPLUS Full-text

DOCUMENT NUMBER: 144:254148

TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
WO 2006018182	A8	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006058311	A1	20060316	US 2005-189540	20050726
PRIORITY APPLN. INFO.:			EP 2004-19361 A	20040814
			EP 2004-19448 A	20040817

OTHER SOURCE(S): MARPAT 144:254148

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof.

The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1313896 HCAPLUS Full-text
DOCUMENT NUMBER: 144:32214
TITLE: Treatment methods utilizing albumin-binding proteins as targets
INVENTOR(S): Trieu, Vuong; Desai, Neil P.; Soon-Shiong, Patrick
PATENT ASSIGNEE(S): American Bioscience, Inc., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117952	A2	20051215	WO 2005-US17174	20050516
WO 2005117952	A3	20060413		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-571622P P 20040514
US 2005-654261P P 20050218

AB The invention provides a method for determining the response of a mammalian tumor to a chemotherapeutic agent comprising detecting and quantifying the SPARC protein in a sample isolated from the human. The invention also provides a method for delivering a chemotherapeutic agent to a tumor in a human that expresses SPARC comprising administering a pharmaceutical composition comprising the chemotherapeutic agent coupled to a compound that binds SPARC protein. The invention further provides a composition comprising a chemotherapeutic agent coupled to a compound capable of binding SPARC protein and a pharmaceutically acceptable carrier.

L24 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:824492 HCAPLUS Full-text
DOCUMENT NUMBER: 143:222525
TITLE: Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function, preparation thereof, and use with other agents
INVENTOR(S): Nirschl, Alexandra A.; Hamann, Lawrence G.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005182105	A1	20050818	US 2005-48437		20050201
PRIORITY APPLN. INFO.:			US 2004-541780P	P	20040204

OTHER SOURCE(S): MARPAT 143:222525
GI



I

AB A method is provided for treating androgen receptor-associated conditions, such as age-related diseases, e.g. sarcopenia, employing a compound I [R1 = CN, H; X = O, S; R2 = (substituted) alkyl, (substituted) cycloalkyl, etc; R3, R4 = H, (substituted) alkyl, etc.; G = (substituted) aryl, (substituted) heteroaryl], or a pharmaceutically acceptable salt or prodrug ester thereof. Preparation of selected I is described. I may be used in combination with other agents.

L24 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:493530 HCAPLUS Full-text
DOCUMENT NUMBER: 143:32415
TITLE: Soft tissue implants and anti-scarring agents
INVENTOR(S): Hunter, William L.; Gravett, David M.; Toleikis, Philip M.; Maiti, Arpita
PATENT ASSIGNEE(S): Angiotech International A.-G., Switz.
SOURCE: PCT Int. Appl., 2592 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051444	A2	20050609	WO 2004-US39465	20041122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005148512	A1	20050707	US 2004-986230	20041110
US 2005181977	A1	20050818	US 2004-986231	20041110
AU 2004293075	A1	20050609	AU 2004-293075	20041122
CA 2536192	A1	20050609	CA 2004-2536192	20041122

WO 2005051232	A2	20050609	WO 2004-US39346		20041122
WO 2005051232	A3	20051208			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2006055008	A2	20060526	WO 2004-US39353		20041122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1687041	A2	20060809	EP 2004-812062		20041122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU

CN 1878514	A	20061213	CN 2004-80033341		20041122
US 2005149158	A1	20050707	US 2004-409		20041129
US 2005175662	A1	20050811	US 2004-451		20041129
US 2005175661	A1	20050811	US 2004-999205		20041129
US 2005186243	A1	20050825	US 2004-97		20041129
US 2005186242	A1	20050825	US 2004-999204		20041129
US 2005191331	A1	20050901	US 2004-1419		20041130
US 2005175663	A1	20050811	US 2004-1791		20041202
US 2005181008	A1	20050818	US 2004-1786		20041202
US 2005181011	A1	20050818	US 2004-1792		20041202
US 2005143817	A1	20050630	US 2004-6899		20041207
US 2005177103	A1	20050811	US 2004-6314		20041207
US 2005177225	A1	20050811	US 2004-6895		20041207
US 2005181004	A1	20050818	US 2004-6289		20041207
US 2006147492	A1	20060706	US 2006-343809		20060131
PRIORITY APPLN. INFO.:			US 2003-523908P	P	20031120
			US 2003-524023P	P	20031120
			US 2003-525226P	P	20031124
			US 2003-526541P	P	20031203
			US 2004-578471P	P	20040609
			US 2004-586861P	P	20040709
			US 2004-986230	A	20041110
			US 2004-986231	A	20041110
			US 2003-518785P	P	20031110
			US 2004-582833P	P	20040624
			US 2004-986450	A1	20041110
			WO 2004-US39346	W	20041122
			WO 2004-US39465	W	20041122

AB The invention relates to soft tissue implants for use in cosmetic or reconstructive surgery and to compns. to make the implants resistant to growth by inflammatory scar tissue. Thus, a silicone gel containing paclitaxel was used as a filling in breast implant.

L24 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:965067 HCAPLUS Full-text
DOCUMENT NUMBER: 141:406039

TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
NO 2005005605	A	20051128	NO 2005-5605	20051128

PRIORITY APPLN. INFO.:

EP 2003-9587	A	20030429
EP 2004-508	A	20040113
EP 2004-1171	A	20040121
WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

L24 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:930955 HCAPLUS Full-text
DOCUMENT NUMBER: 141:395558
TITLE: Preparation of heteroaryl chromenones as inhibitors of tyrosine kinases and/or Raf kinases.
INVENTOR(S): Mujica-Fernaud, Teresa; Buchholz, Herwig; Rautenberg, Wilfried; Sirrenberg, Christian
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1473293	A1	20041103	EP 2004-7549	20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
DE 10335782	A1	20041118	DE 2003-10335782	20030805
US 2004220182	A1	20041104	US 2004-833159	20040428

PRIORITY APPLN. INFO.: DE 2003-10319552 A 20030430
DE 2003-10335782 A 20030805

OTHER SOURCE(S): MARPAT 141:395558
GI



I

AB Title compds. [I; R1-R3 = H, OH, OA, PhO, Ar, O2CA, SO2H, SO3A, OSO2A, SO2A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2; R1R2 = OCH2O, OCH2CH2O; Ar = (substituted) (unsatd.) (aromatic) mono- or binuclear heterocyclyl; A = (fluorinated) alkyl; Ar = (substituted) Ph, naphthyl, biphenyl], were prepared Thus, 1-methylimidazole in THF at -78° was treated with BuLi and then with 6-hydroxy-2-ethoxycarbonylchromen-4-one (preparation given) in THF followed by stirring for 1 h to give 6-hydroxy-2-(1-methyl-1H-imidazol-2-carbonyl)chromen-4-one. The latter inhibited Raf with IC50 >1.0 μM.

L24 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:470326 HCAPLUS Full-text
DOCUMENT NUMBER: 141:38618
TITLE: Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.
INVENTOR(S): Mujica-Fernaud, Teresa; Buchholz, Herwig; Carola, Christophe; Rautenberg, Wilfried; Sirrenberg, Christian
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1426372	A1	20040609	EP 2003-26103	20031113
EP 1426372	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10256182	A1	20040624	DE 2002-10256182	20021202
AT 315564	T	20060215	AT 2003-26103	20031113
ES 2255654	T3	20060701	ES 2003-3026103	20031113

US 2004138464 A1 20040715 US 2003-725346 20031202
PRIORITY APPLN. INFO.: DE 2002-10256182 A 20021202
OTHER SOURCE(S): MARPAT 141:38618
GI



I

AB Title compds. [I; R = A, pyridyl, (substituted) Ph; X = H, OH, PhO, OA, O2CA, SO3H, OSO3H, OSO3A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2, etc.; A = alkyl, fluoroalkyl; n = 1-4], were prepared Thus, 2,5-dihydroxyacetophenone and di-Et oxalate were heated 3 h at 80° in EtOH to give 6-hydroxy-2-ethoxycarbonylchromone. This was refluxed with aqueous HCl in HOAc to give 6-hydroxychromon-2-carboxylic acid. The latter in THF at -10° was treated with Et3N and iso-Bu chloroformate; after stirring for 1 h, 4-tert-butylbenzaldoxime in THF was added followed by stirring for 30 min. at room temperature and at reflux for 90 min. to give 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl] chromone. The latter inhibited Tie2 receptor tyrosine kinase with IC50 >10 μM.

L24 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:466702 HCAPLUS Full-text
DOCUMENT NUMBER: 141:38528
TITLE: Preparation of 2-benzoylchromone derivatives as inhibitors of the tyrosine kinase
INVENTOR(S): Mujica-Fernaud, Teresa; Buchholz, Herwig; Carola, Christophe; Sirrenberg, Christian; Rautenberg, Wilfried
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10256174	A1	20040609	DE 2002-10256174	20021202
EP 1426378	A1	20040609	EP 2003-25849	20031111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004176440	A1	20040909	US 2003-725349	20031202

PRIORITY APPLN. INFO.: DE 2002-10256174 A 20021202
OTHER SOURCE(S): CASREACT 141:38528; MARPAT 141:38528
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB New compds. I [R = OH, OA, OPh, Ar, OC(:O)A, SO3H, SO3A, OSO3H, OSO3A, OSO2A, SO2A, halogen (F, Cl, I, Br), CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2; RR = OCH2O, OCH2CH2O; A = (un)branched C1-10-alkyl, C1-10-fluoroalkyl; Ar = (un)substituted Ph; X =

OH; XX = OCH2O, OCH2CH2O; n = 1 - 4; m = 1 - 5], their pharmaceutically acceptable derivs., solvates and stereoisomers, are inhibitors of the tyrosine kinase and can for the treatment by tumors, to the neuroprotection and for the protection of the stress proteins of the skin is used. The procedure for the preparation of I is characterized by: (a) hydroxyacetophenones II are cyclized with AOC(:O)C(:O)OA (A = C1-6-alkyl) to chromones III ; (b) hydrolysis of III to acid IV; (c) chlorination to acid chloride V ; (d) Friedel-Crafts acylation of PhRm. Thus, 5-Hydroxy-2-(2,4- dihydroxybenzoyl)chromone (VI) was prepared from 2,6-dihydroxyacetophenone via cyclocondensation with (EtO2C)2, hydrolysis with aqueous HCl in MeCO2H, chlorination with with (COCl)2 in CH2Cl2 containing catalytic DMF, then Friedel-Crafts acylation of resorcinol in THF containing AlCl3. Several drug dosage formulations are presented.

L24 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:342284 HCAPLUS Full-text
DOCUMENT NUMBER: 140:350203
TITLE: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
AUTHOR(S): Kantarjian, Hagop; Talpaz, Moshe; O'Brien, Susan; Garcia-Manero, Guillermo; Verstovsek, Srdan; Giles, Francis; Rios, Mary Beth; Shan, Jianqin; Letvak, Laurie; Thomas, Deborah; Faderl, Stefan; Ferrajoli, Alessandra; Cortes, Jorge
CORPORATE SOURCE: Departments of Leukemia and Bioimmunotherapy, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA
SOURCE: Blood (2004), 103(8), 2873-2878
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual mol. disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 mo, no patient has progressed to accelerated or blastic phase. The estimated 2-yr survival rate was 94%. By quant. polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P =.0005), major mol. response (QPRC < 0.05%; P =.00001), and complete mol. response (undetectable BCR-ABL; P =.001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of mol. response in patients with newly diagnosed chronic phase CML.
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:100803 HCAPLUS Full-text
DOCUMENT NUMBER: 140:139483
TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004023925	A1	20040205	US 2003-408723	20030407
US 2003013681	A1	20030116	US 2002-176235	20020620
US 6680306	B2	20040120		
CN 1543351	A	20041103	CN 2002-816003	20020621
US 2004043962	A1	20040304	US 2003-657383	20030908
AU 2004229399	A1	20041028	AU 2004-229399	20040407
CA 2521649	A1	20041028	CA 2004-2521649	20040407
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1617849	A1	20060125	EP 2004-759200	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522163	T	20060928	JP 2006-509773	20040407
PRIORITY APPLN. INFO.:			US 2001-299991P	P 20010621
			US 2002-176235	A2 20020620
			US 2003-408723	A 20030407
			US 2003-461006P	P 20030407
			US 2003-474562P	P 20030530
			WO 2004-US10675	W 20040407

AB The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.

L24 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41226 HCAPLUS Full-text
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2491466	A1	20040115	CA 2003-2491466	20030709
AU 2003265264	A1	20040123	AU 2003-265264	20030709
US 2004077601	A1	20040422	US 2003-616694	20030709
US 2005084490	A1	20050421	US 2003-616409	20030709
EP 1578434	A2	20050928	EP 2003-763380	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T	20060302	JP 2004-562634	20030709
CN 1802090	A	20060712	CN 2003-821282	20030709
CN 1826129	A	20060830	CN 2003-821281	20030709
PRIORITY APPLN. INFO.:			US 2002-394856P P	20020709
			US 2002-414978P P	20021001
			US 2003-466435P P	20030428
			WO 2003-US21405 W	20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

L24 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:13818 HCAPLUS Full-text
DOCUMENT NUMBER: 138:32998
TITLE: Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia
AUTHOR(S): Liu, Nina Shih; O'Brien, Susan
CORPORATE SOURCE: Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA
SOURCE: Leukemia & Lymphoma (2002), 43(12), 2413-2415
CODEN: LELYEA; ISSN: 1042-8194
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Imatinib mesylate, a specific inhibitor of the BCR-ABL tyrosine kinase, has been very effective in the treatment of chronic myeloid leukemia (CML) in chronic phase with high rates of hematol. and cytogenetic remissions. Resistance to therapy can develop and transformation to blast crisis may occur, particularly in patients without a cytogenetic response. We report a case of a patient with CML treated in chronic phase who developed blast crisis; withdrawal of imatinib mesylate resulted in spontaneous reversion to chronic phase.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:507951 HCAPLUS Full-text
DOCUMENT NUMBER: 135:87148
TITLE: Metal ion binding site-based method of identifying ligands of biological target molecules for drug discovery
INVENTOR(S): Elling, Christian E.; Gerlach, Lars Ole; Holst Lange, Birgitte; Pedersen, Jan Torleif; Schwartz, Thue W.
PATENT ASSIGNEE(S): 7TM Pharma, Den.
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001050127	A2	20010712	WO 2000-EP13389	20001229
WO 2001050127	A3	20020131		
WO 2001050127	A9	20020912		
WO 2001050127	A8	20040219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2395999	A1	20010712	CA 2000-2395999	20001229
US 2002061599	A1	20020523	US 2000-752102	20001229
EP 1242824	A2	20020925	EP 2000-993741	20001229

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

WO 2002054077	A2	20020711	WO 2001-DK867	20011221

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
DK 1999-1879	A	19991230
DK 1999-1880	A	19991230
US 2000-175401P	P	20000111
US 2000-175994P	P	20000111
DK 2000-705	A	20000428
US 2000-202990P	P	20000509
WO 2000-EP13389	W	20001229
DK 2001-536	A	20010330
US 2001-280237P	P	20010330

OTHER SOURCE(S): MARPAT 135:87148

AB The invention provides a mol. approach for rapidly and selectively identifying small organic mol. ligands, i.e. compds., that are capable of interacting with and binding to specific sites on biol. target mols. The methods of the invention are applicable to any biol. target mol. that has or can be manipulated to have a metal-ion binding site. Biol. target mols. are e.g. proteins, polypeptides, oligopeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids, lipoproteins and derivs. thereof. More specifically, the biol. target mols. include membrane receptors, signal transduction proteins, scaffolding proteins, nuclear receptors, steroid receptors, intracellular receptors, transcription factors, enzymes, allosteric enzyme regulatory proteins, growth factors, hormones, neuropeptides and Igs. A very interesting group of biol. target mols. are membrane proteins such as, e.g., transmembrane protein (e.g. 7 TMs). The methods described herein make it possible to construct and screen libraries of compds. specifically directed against predetd. epitopes on the biol. target mols. The compds. are initially constructed to be bifunctional, i.e. having both a metal-ion binding moiety, which conveys them with the ability to bind to either a natural or an artificially constructed metal-ion binding site as well as a variable moiety, which is varied chemical to probe for interactions with specific parts of the biol. target mol. located spatially adjacent to the metal-ion binding site. Compds. may subsequently be further modified to bind to the unmodified biol. target mol. without help of the bridging metal-ion. The methods according to the invention may be performed easily and quickly and lead to unambiguous results. The compds. identified by the methods may themselves be

employed for various applications or may be further derivatized or modified to provide novel compds. The methodol. of the invention is useful in drug discovery.

L24 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:394904 HCAPLUS Full-text
DOCUMENT NUMBER: 135:174865
TITLE: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
AUTHOR(S): Kano, Yasuhiko; Akutsu, Miyuki; Tsunoda, Saburo; Mano, Hiroyuki; Sato, Yuko; Honma, Yoshio; Furukawa, Yusuke
CORPORATE SOURCE: Division of Hematology and Medical Oncology, Tochigi Cancer Center, Tochigi, 320-0834, Japan
SOURCE: Blood (2001), 97(7), 1999-2007
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The BCR/ABL tyrosine kinase has been implicated in the pathogenesis of chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL). STI571 is a novel anticancer agent that selectively inhibits the BCR/ABL tyrosine kinase. The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph+ leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y. The cells were exposed to STI571 and to other agents simultaneously for 5 or 7 days. Cell growth inhibition was determined by MTT assay. The cytotoxic effects in combinations at the inhibitory concentration of 80% level were evaluated by the isobologram. STI571 produced synergistic effects with recombinant and natural α-interferons in 2 of 3 and 3 of 3 cell lines, resp. STI571 produced additive effects with hydroxyurea, cytarabine, homoharringtonine, doxorubicin, and etoposide in all 4 cell lines. STI571 with 4-hydroperoxy-cyclophosphamide, methotrexate, or vincristine produced additive, antagonistic, and synergistic effects in 3 of 4 cell lines, resp. These findings suggest that the simultaneous administration of STI571 with other agents except methotrexate would be advantageous for cytotoxic effects against Ph+ leukemias. Among them, the simultaneous administration of STI571 and α-interferons or vincristine would be highly effective against Ph+ leukemias and these combinations would be worthy of clin. trials. In contrast, the simultaneous administration of STI571 with methotrexate would have little therapeutic efficacy. Although there are gaps between in vitro studies and clin. trials, the present findings provide useful information for the establishment of clin. protocols involving STI571.
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:99301 HCAPLUS Full-text
DOCUMENT NUMBER: 116:99301
TITLE: Maleic anhydride copolymers as antidotes for the cytotoxicity of neoplasm inhibitors
INVENTOR(S): Bach, Ardalan; Shanahan, William R., Jr.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393575	A1	19901024	EP 1990-107246	19900417
EP 393575	B1	19940316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2014732	A1	19901017	CA 1990-2014732	19900417
JP 02292227	A	19901203	JP 1990-101530	19900417
AT 102838	T	19940415	AT 1990-107246	19900417

ES 2062155	T3	19941216	ES 1990-107246		19900417
PRIORITY APPLN. INFO.:			US 1989-339503	A	19890417
			EP 1990-107246	A	19900417

OTHER SOURCE(S): MARPAT 116:99301
GI



I

AB Half-amide:half-imide copolymers comprising ethylene and maleic anhydride moieties (structure given), specifically carbetimer (I; a/b = 1:2-5), decrease the cytotoxic side effects of neoplasm inhibitors. Mice treated i.v. with 21 mg adriamycin/kg died within 5 days. When 1700 mg I/kg was administered concomitantly, no lethality was shown for >30 days.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	89.85	437.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.25	-14.25

FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=>
=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.64	440.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-14.25

FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	1.26	441.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-14.25

FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s flavanoid?
L27        1300 FLAVANOID?

=> s kinase
         279466 KINASE
          54347 KINASES
L28      288351 KINASE
                (KINASE OR KINASES)

=> s l27 and l28
L29          14 L27 AND L28

=> d l29 ibib
```

L29 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2006:1220504 HCAPLUS Full-text
TITLE:	Apigenin inhibition of involucrin gene expression is associated with a specific reduction in phosphorylation of protein kinase Cδ Tyr311
AUTHOR(S):	Balasubramanian, Sivaprakasam; Zhu, Ling; Eckert, Richard L.
CORPORATE SOURCE:	Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4970, USA
SOURCE:	Journal of Biological Chemistry (2006), 281(47), 36162-36172 CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER:	American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE:	Journal
LANGUAGE:	English
REFERENCE COUNT:	85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l29 ibib 2

L29  ANSWER 2 OF 14  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:584435  HCAPLUS  Full-text
DOCUMENT NUMBER:         145:137165
TITLE:                   Prostate cancer chemoprevention by Silibinin: bench to
                         bedside
AUTHOR(S):               Singh, Rana P.; Agarwal, Rajesh
CORPORATE SOURCE:        Department of Pharmaceutical Sciences, School of
                         Pharmacy, University of Colorado at Denver and Health
                         Sciences Center, Denver, CO, USA
SOURCE:                  Molecular Carcinogenesis (2006), 45(6), 436-442
                         CODEN: MOCAE8; ISSN: 0899-1987
PUBLISHER:               Wiley-Liss, Inc.
DOCUMENT TYPE:           Journal; General Review
LANGUAGE:                English
REFERENCE COUNT:         20    THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s tyrosine kinase
        155428 TYROSINE
          2627 TYROSINES
        155960 TYROSINE
                 (TYROSINE OR TYROSINES)
        279466 KINASE
         54347 KINASES
        288351 KINASE
                 (KINASE OR KINASES)
L30      42816 TYROSINE KINASE
                 (TYROSINE(W)KINASE)

=> s l30 and l29
L31           3 L30 AND L29

=> d l31 ibib abs

L31  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:584435  HCAPLUS  Full-text
DOCUMENT NUMBER:         145:137165
TITLE:                   Prostate cancer chemoprevention by Silibinin: bench to
                         bedside
AUTHOR(S):               Singh, Rana P.; Agarwal, Rajesh
CORPORATE SOURCE:        Department of Pharmaceutical Sciences, School of
                         Pharmacy, University of Colorado at Denver and Health
                         Sciences Center, Denver, CO, USA
SOURCE:                  Molecular Carcinogenesis (2006), 45(6), 436-442
                         CODEN: MOCAE8; ISSN: 0899-1987
PUBLISHER:               Wiley-Liss, Inc.
DOCUMENT TYPE:           Journal; General Review
LANGUAGE:                English
AB    A review.  Prostate cancer (PCA) is the most invasive malignancy and second leading cause
      of cancer deaths in American males.  One approach to reduce PCA incidence, growth, and
      metastasis is prevention and intervention targeted towards mitogenic and survival
      signaling and cell-cycle regulation.  This approach is based on the rationale that
      overexpression of receptor tyrosine kinases (RTKs) and(or) non-receptor tyrosine kinases
      leads to persistent autocrine stimulation of malignant cells for deregulated cell-cycle
      progression and uncontrolled growth.  PCA progression has also been associated with
      transition from a paracrine to an autocrine relation between receptors and growth ligands
      as this malignancy progresses to an advanced androgen-independent aggressive stage.
      Together, these studies suggest that targeting RTK-mediated signaling pathways along with
      cell-cycle regulators could be a practical and translational approach for PCA prevention
      and intervention.  Here, the authors provide evidence that a naturally occurring nontoxic
      flavanoid, Silibinin, targets the epidermal growth factor receptor (EGFR), insulin-like
```

growth factor-1 receptor (IGF-1R), and NF-κB (nuclear factor-kappa B) pathways in PCA. Furthermore, it modulates cell-cycle regulators, including cyclin-dependent kinases (CDKs), Cip/Kip, and cyclins for its anticancer efficacy against PCA. Silibinin inhibits the growth of PCA cells from human, mouse, and rat origins, and also suppresses human prostate tumor xenograft growth in nude mice. Silibinin also inhibits PCA growth in the transgenic adenocarcinoma of mouse prostate (TRAMP) mouse model. Now, Silibinin has beer entered into phase I/II clin. trials in human PCA patients where preliminary observations were suggestive of its further study in a larger base of the patient population.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l31 ibib abs 2-6

L31 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:45494 HCAPLUS Full-text
DOCUMENT NUMBER: 128:119463
TITLE: The plans of the genus Phyllanthus as a potential source of new drugs
AUTHOR(S): Calixto, Joao B.; Santos, Adair R. S.; Paulino, Niraldo; Cechinel Filho, Valdir; Yunes, Rosendo A.
CORPORATE SOURCE: Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianopolis, 88015-420, Brazil
SOURCE: Ciencia e Cultura (Sao Paulo) (1997), 49(5/6), 422-432
CODEN: CCUPAD; ISSN: 0009-6725
PUBLISHER: Sociedade Brasileira para o Progresso da Ciencia
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 157 refs. The plants of the genus Phyllanthus (Euphorbiaceae) comprise about 550 to 750 species which are widely distributed in most tropical and subtropical countries. About 200 species are believed to occur in the Americas, mainly in the Caribbean and Brazil. The plants of the genus Phyllanthus have long been used in folk medicine to treat, among others, kidney and urinary bladder disorders, intestinal infections, diabetes and hepatitis B. In recent years, substantial progress in chemical and pharmacol. studies, and a few clin. studies of some Phyllanthus species, were made. This review discusses the current knowledge gained by the in vitro and in vivo pharmacol. and biochem. studies performed with the exts. and the main active constituents isolated from different species of plants of the genus Phyllanthus. Data available in the literature strongly support the idea that th extract and some constituents isolated from these plants, including flavanoids, tannins, alkaloids, coumarins, lignans and terpenes, account for their reported antinociceptive, anti-inflammatory, antiviral, antispasmodic and antiallergic properties. In addition, some of these compds. interact with most key enzymes, such as aldose reductase, angiotensin converting enzyme, mitochondrial ATPase, both cyclo- and lipooxygenases, phospholipase A2, tyrosine kinase, reverse transcriptase, and phosphodiesterases. The complex mechanism of action of such compds. could explain, at least in part, the wide therapeutic use of the plants of the genus Phyllanthus in folk medicine. Thus, the plants of the genus Phyllanthus present potential therapeutic interest as a source of new drugs.

REFERENCE COUNT: 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:32520 HCAPLUS Full-text
DOCUMENT NUMBER: 112:32520
TITLE: Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds
AUTHOR(S): Geahlen, Robert L.; Koonchanok, Nuphavan M.; McLaughlin, Jerry L.; Pratt, Dan E.
CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA
SOURCE: Journal of Natural Products (1989), 52(5), 982-6
CODEN: JNPRDF; ISSN: 0163-3864
DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of 22 flavanoids and related compds. were tested for their ability to inhibit the activity of a protein-tyrosine kinase purified from bovine thymocytes (p40). Flavones or flavanols with hydroxyl groups at C-5 and C-7 or with 3 hydroxyl groups on the Ph ring were potent inhibitors of p40. The replacement of hydroxyl groups with methoxyl groups led to a substantial loss of inhibitory activity. The presence of methoxyl or rhamnosyl substituents at C-3 also abolished inhibitory activity. Kinetic analyses indicated that the flavone apigenin was a competitive inhibitor of p40 with respect to ATP. Flavanones and isoflavones were relatively inactive as protein- tyrosine kinase inhibitors. The isoflavone genistein, which has been reported as a potent inhibitor of both pp60 and the epidermal growth factor receptor, was not an inhibitor of p40.

```
=> f stng
L32          2 STNG

=> file stng
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      20.62     462.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.25     -16.50

FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> d his

     (FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3          47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4          83 S L3
L5          77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6           0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7           0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8             STRUCTURE UPLOADED
L9          50 S L8 SSS SAM
L10       9805 S L8 SSS FULL
```

```
     FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11         9054 S L10
L12            0 S L11 AND L5
L13            0 S L11 AND L4
L14            6 S L10 AND CHROMENE
L15          490 S L10 AND KINASE
L16           94 S L10 AND TYROSINE KINASE
                 E MUJICA F/AU 25
L17            6 S (E5 OR E6)
                 E BUCHHOLZ H/AU 25
L18          148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)
                 E CAROLA C/AU 25
L19           37 S (E3 OR E5)
                 E RAUTENBERG W/AU 25
L20           49 S (E3 OR E5 OR E7)
                 E SURREBBERG C/AU 25
                 E SIRRENBERG C/AU 25
L21           33 S (E4)
L22          333 S L16 OR L17 OR L18 OR L19 OR L20 OR L21
L23          131 S L22 AND KINASE
L24           18 S L23 AND CHROM?
L25            0 S L24 AND L4
L26            0 S L23 AND L4

     FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

     FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006
L27         1300 S FLAVANOID?
L28       288351 S KINASE
L29           14 S L27 AND L28
L30        42816 S TYROSINE KINASE
L31            3 S L30 AND L29
L32            2 F STNG

     FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

=> fil hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    0.12      462.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    0.00      -16.50

FILE 'HCAPLUS' ENTERED AT 18:55:11 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.18	477.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.50

FILE 'STNGUIDE' ENTERED AT 18:58:47 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	477.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.50

FILE 'HCAPLUS' ENTERED AT 18:59:14 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

```
L3           47 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4           83 S L3
L5           77 S L4 AND 1800<=PY<=2001

     FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6            0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7            0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

     FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

     FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8               STRUCTURE UPLOADED
L9           50 S L8 SSS SAM
L10        9805 S L8 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11        9054 S L10
L12           0 S L11 AND L5
L13           0 S L11 AND L4
L14           6 S L10 AND CHROMENE
L15         490 S L10 AND KINASE
L16          94 S L10 AND TYROSINE KINASE
                E MUJICA F/AU 25
L17           6 S (E5 OR E6)
                E BUCHHOLZ H/AU 25
L18         148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)
                E CAROLA C/AU 25
L19          37 S (E3 OR E5)
                E RAUTENBERG W/AU 25
L20          49 S (E3 OR E5 OR E7)
                E SURREBBERG C/AU 25
                E SIRRENBERG C/AU 25
L21          33 S (E4)
L22         333 S L16 OR L17 OR L18 OR L19 OR L20 OR L21
L23         131 S L22 AND KINASE
L24          18 S L23 AND CHROM?
L25           0 S L24 AND L4
L26           0 S L23 AND L4

     FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

     FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006
L27        1300 S FLAVANOID?
L28      288351 S KINASE
L29          14 S L27 AND L28
L30       42816 S TYROSINE KINASE
L31           3 S L30 AND L29
L32           2 F STNG

     FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:55:11 ON 19 DEC 2006

     FILE 'STNGUIDE' ENTERED AT 18:58:47 ON 19 DEC 2006

     FILE 'HCAPLUS' ENTERED AT 18:59:14 ON 19 DEC 2006

=> s oxal?
L33      122622 OXAL?
```

```
=> s l33 and l16
L34         20 L33 AND L16

=> s l33 and l17
L35          3 L33 AND L17

=> s l33 and l5
L36         11 L33 AND L5

=> d l36 ibib abs hitstr

L36  ANSWER 1 OF 11  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:300703  HCAPLUS  Full-text
DOCUMENT NUMBER:          134:311230
TITLE:                    Preparation of benzopyran derivatives as adrenergic
                          antagonists
INVENTOR(S):              Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Sironi,
                          Giorgio
PATENT ASSIGNEE(S):       Recordati Industria Chimica E Farmaceutica Spa, Italy;
                          Recordati S. A., Chemical and Pharmaceutical Company
SOURCE:                   PCT Int. Appl., 61 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    ---------------------    --------
     WO 2001029022         A1    20010426    WO 2000-EP10143          20001016 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     IT 99MI2174           A1    20010418    IT 1999-MI2174           19991018 <--
     IT 1314192            B1    20021206
     EP 1222183            A1    20020717    EP 2000-975868           20001016
     EP 1222183            B1    20030423
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003512366         T     20030402    JP 2001-531822           20001016
     AT 238291             T     20030515    AT 2000-975868           20001016
     PT 1222183            T     20030829    PT 2000-975868           20001016
     ES 2197123            T3    20040101    ES 2000-975868           20001016
     US 6403594            B1    20020611    US 2000-691770           20001018
PRIORITY APPLN. INFO.:                         IT 1999-MI2174       A  19991018
                                               US 2000-218721P      P  20000717
                                               WO 2000-EP10143      W  20001016
OTHER SOURCE(S):          MARPAT 134:311230
GI
```



I

AB N-(4-phenylpiperazin-1-ylalkyl)-2-oxobenzopyran-8-carboxamide derivs. (I; R = Ph, alkoxycarbonyl, alkylcarbonyl, CONH2, CONH(alkyl), CON(alkyl)2, cyano, or alkoxycarbonylamino; R2 = alkyl, alkoxy, polyfluoroalkoxy, OH, or CF3SO2O; each of R4 anc R5 independently = H, halogen, polyfluoroalkyl, polyfluoroalkoxy, cyano or CONH2; n is 0, 1 or 2; but if R = Ph and both of R4 and R5 = H or hologen atoms, then R2 = polyfluoroalkoxy or CF3SO2O) and their N-oxides and pharmaceutically acceptable salts are prepared These compds. are endowed with adrenergic antagonist activity and, in particular, with high selectivity for the α1-adrenergic receptor as compared to the 5-HT1A receptor. This activity profile suggests the use of these benzopyran derivs. for preventing contractions (including noradrenaline-related contractions) of the uretha and lower urinary tract in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), without side-effects associated with hypotensive activity. They are also useful for treating high intraocular pressure, cardiac arrhythmia, or sexual dysfunction, inhibiting the synthesis of cholesterol, and reducing sympathetically- mediated pain. Thus, 1-(3-aminopropyl)-4-(5-chloro-2-methoxyphenyl)piperazine trihydrochloride was condensed with 8-Carboxy-2-((1,1-dimethylethoxycarbonyl)amino)-3-methyl-4H-1-benzopyran using di-Et cyanophosphate in the presence of Et3N in DMF at 0-25° for 4 h to give 2-((1,1-dimethylethoxycarbonyl)amino)-8-[[3-[4-(5-chloro-2- methoxyphenyl)-1-piperazinyl]propyl]carbamoyl]-3-methyl-4-oxo-4H-1-benzopyran monohydrate which in vitro showed affinity to cloned α1a, α1b, α1d, and 5-HT1A receptor with Ki of 0.20, 0.32, 0.45, and 81.87 nM, resp.

IT 335086-82-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzopyran derivs. as α1-adrenergic antagonists for treating diseases associated with overactivity of said receptor)

RN 335086-82-3 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 3-methyl-4-oxo-8-(1-propenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l36 ibib abs hitstr 2-16

L36 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:156223 HCAPLUS Full-text
DOCUMENT NUMBER: 106:156223

TITLE: Benzopyrones. Part 23. Cyclization of o-amino carboxamides and related compounds

AUTHOR(S): Bevan, Peter S.; Ellis, Gwynn P.; Hudson, Henrietta V.; Romney-Alexander, Trevor M.; Williams, J. Michael

CORPORATE SOURCE: Inst. Sci. Technol., Univ. Wales, Cardiff, CF1 3XF, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1986), (9), 1643-9
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:156223

GI



I



II



III



IV



V

AB Cyclization of chromenecarboxamide I (R = H, R1 = Br, R2 = NH2, R3 = CONH2) with EtO2CCO2Et-NaOEt gave the benzopyranopyrimidinedione II. I (R = H, R1 = CO2Et, R2 = CONH2, R3 = NH2) in a similar reaction gave benzopyranopyrimidine III but when I (R, R1 = H, R2 = CONH2, R3 = NH2) was subjected to the same reaction, benzopyranodiazepine IV was obtained in high yield. This structure, which contains the hitherto unknown 1,4-diazepine-2,3,5-trione ring, is supported by spectroscopic and chemical evidence. The presence of a 3-amino and a 2-carbonyl group in a chromone has an unexpected shielding effect on the chemical shift of C-8. The course of the cyclization was studied. Attempts to cyclize I(R, R1 = H, R2 = CONH2, R3 = CH2NH2) failed but a new ring system V was obtained when I (R, R1 = H, R2 = CO2Et, R3 = Br) reacted with 2-H2NC6H4NH2.

IT 107691-27-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of)

RN 107691-27-0 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 3-bromo-4-oxo- (9CI) (CA INDEX NAME)



L36 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:119624 HCAPLUS Full-text
DOCUMENT NUMBER: 106:119624
TITLE: Synthesis of 14C-bucromarone succinate and hydrochloride
AUTHOR(S): Nicolas, Colette; Verny, Michel; Maurizis, Jean Claude; Payard, Marc; Faurie, Michel
CORPORATE SOURCE: INSERM U 71, Clemont-Ferrand, 63005, Fr.
SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1986), 23(8), 837-44
CODEN: JLCRD4; ISSN: 0362-4803
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:119624
GI



I

AB 14C-bucromarone I was prepared from HO214C14CO2H. The labeling took place at the first step of the synthesis, and 14C-bucromarone succinate, with a specific activity of 7.45 mCi/mmol, and 14C-bucromarone hydrochloride, with a specific activity of 7.5 mCi/mmol, were obtained.

IT 107139-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Friedel-Crafts reaction of, with dimethylphenol)

RN 107139-53-7 HCAPLUS

CN 4H-1-Benzopyran-2-14C-2-carbonyl-14C chloride, 4-oxo- (9CI) (CA INDEX NAME)



L36 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:103331 HCAPLUS Full-text
DOCUMENT NUMBER: 94:103331
TITLE: Heterocyclic nitrogen derivatives
INVENTOR(S): Cox, David; Cairns, Hugh; Chadwick, Nigel; Suschitzky, John Louis
PATENT ASSIGNEE(S): Fisons Ltd., UK
SOURCE: Ger. Offen., 122 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent



I



II



III



IV

AB Antiallergic (no data) pyrano[3,2-d]quinolinedicarboxylic acids and related compds. were prepared Thus, the aniline I was treated with MeO2CC.tplbond.CCO2Me and the resulting fumarate cyclized to give II which was chlorinated and treated with MeNH2 to give the diamide III. III was hydrolyzed and esterified to the Et ester which was treated with di-Et oxalate to give the ester IV (R = Et). The latter was saponified to IV (R = Na).

IT 75453-71-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 75453-71-3 HCAPLUS

CN 4H-Pyrano[3,2-g]quinoline-2,8-dicarbonyl dichloride, 6-chloro-4-oxo-10-propyl- (9CI) (CA INDEX NAME)



L36 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:30488 HCAPLUS Full-text

DOCUMENT NUMBER: 94:30488

TITLE: Benzopyrones. Part 16. Synthesis of 3-alkyl-4-oxochromen-2-carboxylic acids, 3-alkyl-2-methylchromen-4-ones, and related compounds

AUTHOR(S): Buggy, Thomas; Ellis, Gwynn P.

CORPORATE SOURCE: Dep. Chem., Univ. Wales Inst. Sci. Technol., Cardiff, CF1 3NU, UK

SOURCE: Journal of Chemical Research, Synopses (1980), (9), 317
CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 94:30488

GI

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
DE 2943658	A1	19800514	DE 1979-2943658	19791029	<--
DE 2943658	C2	19910801			
GB 2035312	A	19800618	GB 1979-36401	19791019	<--
GB 2035312	B	19821020			
FR 2440371	A1	19800530	FR 1979-26530	19791025	<--
FR 2440371	B1	19830128			
CA 1142520	A1	19830308	CA 1979-338555	19791026	<--
FI 7903369	A	19800501	FI 1979-3369	19791029	<--
FI 67702	B	19850131			
FI 67702	C	19850510			
NL 7907916	A	19800502	NL 1979-7916	19791029	<--
NO 7903469	A	19800502	NO 1979-3469	19791029	<--
NO 154522	B	19860630			
NO 154522	C	19861008			
AU 7952287	A	19800508	AU 1979-52287	19791029	<--
AU 528648	B2	19830505			
BR 7907006	A	19800715	BR 1979-7006	19791029	<--
ZA 7905789	A	19801126	ZA 1979-5789	19791029	<--
PL 130691	B1	19840831	PL 1979-219304	19791029	<--
CS 231166	B2	19841015	CS 1979-7359	19791029	<--
IL 58579	A	19851231	IL 1979-58579	19791029	<--
BE 879737	A1	19800430	BE 1979-197902	19791030	<--
DK 7904586	A	19800501	DK 1979-4586	19791030	<--
SE 7908995	A	19800501	SE 1979-8995	19791030	<--
SE 451071	B	19870831			
SE 451071	C	19871210			
JP 55064572	A	19800515	JP 1979-139422	19791030	<--
JP 03018639	B	19910313			
ES 485517	A1	19800901	ES 1979-485517	19791030	<--
DD 146954	A5	19810311	DD 1979-216552	19791030	<--
SU 1014476	A3	19830423	SU 1979-2838414	19791030	<--
HU 26391	A2	19830928	HU 1979-FI718	19791030	<--
HU 183087	B	19840428			
CH 643264	A5	19840530	CH 1979-9715	19791030	<--
AT 7907014	A	19850715	AT 1979-7014	19791030	<--
AT 379811	B	19860310			
US 4419352	A	19831206	US 1981-236329	19810220	<--
FI 8103127	A	19811008	FI 1981-3127	19811008	<--
NO 8502258	A	19800502	NO 1985-2258	19850604	<--
NO 156692	B	19870727			
NO 156692	C	19871104			

PRIORITY APPLN. INFO.:

GB 1978-42679	A	19781031
GB 1979-20760	A	19790614
US 1979-82994	A1	19791009
GB 1979-36401	A	19791019
FI 1979-3369	A	19791029

GI



AB Novel 3-alkylchromen-4-ones were prepared by 2 previously reported methods. Thus, using the method of W. D. Ollis et al. (1953), the decanophenone I (R = H, R1 = Me) was reactec to give 58% oxochromenecarboxylic acid which was converted to its n-hexyl ester II [R = H, R1 = Me, R2 = CO2(CH2)5Me]. By the Kostanecki-Robinson reaction, the decanophenone I (R = OH, R1 = H) was refluxed with Ac2O/NaOAc for 56 h to give the chromenone II (R = OAc, R1 = H, R2 = Me). The new type of chromenone, III, was prepared using this method.

IT 76115-99-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of)

RN 76115-99-6 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 6-methyl-3-octyl-4-oxo- (9CI) (CA INDEX NAME)



L36 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1977:72660 HCAPLUS Full-text

DOCUMENT NUMBER: 86:72660

TITLE: Chromone and thiachromone carboxyamido tetrazoles

INVENTOR(S): Augstein, Joachim; Cairns, Hugh; Rogers, Norman Harold

PATENT ASSIGNEE(S): Fisons Ltd., UK

SOURCE: Brit., 21 pp. Division of Brit. 1,447,479.
CODEN: BRXXAA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1447480	A	19760825	GB 1973-39041	19731129 <--
DE 2361490	A1	19740627	DE 1973-2361490	19731210 <--
FR 2210405	A1	19740712	FR 1973-44703	19731214 <--
JP 49094675	A	19740909	JP 1973-138874	19731214 <--

PRIORITY APPLN. INFO.:

GB 1972-57901	A	19721215
GB 1973-39041	A	19730817
GB 1973-39042	A	19730817
GB 1973-39044	A	19730817
GB 1973-39045	A	19730817

GI



I



II

AB The chromones I [R = R1 = H, R2 = Me, PhCH2; R = Me2CH(CH2)2O, R1 = allyl, R2 = H; R = 4-ClC6H4O(CH2)2O, R1 = Pr, R2 = H], II (R = H, PhCH2), and their Na salts, useful in the treatment of asthma, were prepared from 4-oxo-4H-1-benzopyran-2-carbonyl chlorides or 5,5'-[(2- formyloxytrimethylene)dioxy]bis[5-(4-oxo-4H-1-benzopyran-2-carbonyl chloride] by treatment with aminotetrazoles. Thus, I (R = R1 = H, R2 = Me) was prepared by stirring 4-oxo-4H-1-benzopyran-2-carbonyl chloride with 5-amino-1-methyltetrazole and Et3N in AcNMe2 2.5 hr at 21°.

IT 5112-47-0 42047-74-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation with aminotetrazoles)

RN 5112-47-0 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 42047-74-5 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 5-(3-methylbutoxy)-4-oxo-8-(2-propenyl)- (9CI) (CA INDEX NAME)



IT 53542-83-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation with aminotetrazole)

RN 53542-83-9 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[[2-(formyloxy)-1,3-propanediyl]bis(oxy)]bis[4-oxo- (9CI) (CA INDEX NAME)



L36 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:413871 HCAPLUS Full-text
DOCUMENT NUMBER: 85:13871
TITLE: Study of the pharmacodynamic properties of heptaminol chromonecarboxamide in the central nervous system
AUTHOR(S): Foussard-Blanpin, Odette; Moreau, C.; Niviere, P.
CORPORATE SOURCE: Lab. Pharmacodyn. Chim. Ther., U.E.R. Sci. Pharm., Tours, Fr.
SOURCE: Therapie (1975), 30(6), 877-86
CODEN: THERAP; ISSN: 0040-5957
DOCUMENT TYPE: Journal
LANGUAGE: French
GI



I

AB While heptaminol-HCl [543-15-7] (120 or 240 mg/kg, orally) facilitated exploratory behavior, slightly increased rectal temperature, and increased excitability in mice, heptaminol-2-chromonecarboxamide (I) [58243-46-2] (250 or 500 mg/kg, orally) had a depressive effect on these parameters. I attenuated the behavioral response to and toxicity of amphetamine, prolonged chloral hydrate- or pentobarbital-induced sleep, enhanced reserpine-induced palpebral ptosis and increased the hypothermic and cataleptic response to chlorpromazine. Heptaminol-HCl increased amphetamine toxicity and behavioral excitation and decreased the response to neuroleptics and hypnotics. The preparation of I is described.

IT 5112-47-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with heptaminol)

RN 5112-47-0 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L36 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:520633 HCAPLUS Full-text
DOCUMENT NUMBER: 81:120633
TITLE: 4-Oxo-4H-1-benzopyran and 4-oxo-4H-1-thiobenzopyron derivatives
INVENTOR(S): Augstein, Joachim; Cairns, Hugh; Rogers, Norman Harold
PATENT ASSIGNEE(S): Fisons Ltd.
SOURCE: Ger. Offen., 45 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2361490	A1	19740627	DE 1973-2361490	19731210 <--
GB 1447479	A	19760825	GB 1972-57901	19731129 <--
GB 1447480	A	19760825	GB 1973-39041	19731129 <--

PRIORITY APPLN. INFO.:

GB 1972-57901	A	19721215
GB 1973-39041	A	19730817
GB 1973-39042	A	19730817
GB 1973-39044	A	19730817
GB 1973-39045	A	19730817

GI For diagram(s), see printed CA Issue.

AB Immunosuppressant (no data) benzopyrancarboxamidotetrazoles I (R = Me, CH2-Ph, R1 = R2 = H; R = H, R1 = OCH2CH2CHMe2, R2 = allyl; R = H, R1 = OCH2CH2OC6H4Cl-p, R2 = Pr) and II (R = H, CH2Ph) were prepared Thus, 2.7 g 4-oxo-4H-1-benzopyran-2-carbonyl chloride was treated with 1.3 g 5-amino-1-methyltetrazole to give 1.2 g I (R = Me, R1 = R2 = H).

IT 53542-83-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with aminotetrazoles)

RN 53542-83-9 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[[2-(formyloxy)-1,3-propanediyl]bis(oxy)]bis[4-oxo- (9CI) (CA INDEX NAME)



IT 5112-47-0 42047-74-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aminotetrazole)

RN 5112-47-0 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

INDEX NAME)



L36 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:82666 HCAPLUS Full-text
DOCUMENT NUMBER: 80:82666
TITLE: Antiallergic 5-ethoxy-2-chromonecarboxylic acid derivatives
INVENTOR(S): Umio, Suminori; Ueda, Ikuo; Sato, Yoshinari; Matsuo, Masaaki; Nakaguti, Osamu; Kobayashi, Masakazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd.
SOURCE: Ger. Offen., 30 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2331138	A1	19740110	DE 1973-2331138	19730619 <--
JP 49020177	A	19740222	JP 1972-62626	19720621 <--
JP 49020179	A	19740222	JP 1972-63407	19720624 <--
JP 49024967	A	19740305	JP 1972-65573	19720629 <--
JP 56035670	B	19810819		

PRIORITY APPLN. INFO.: JP 1972-62626 A 19720621
JP 1972-63407 A 19720624
JP 1972-65573 A 19720629

OTHER SOURCE(S): CASREACT 80:82666
GI For diagram(s), see printed CA Issue.
AB Seventeen chromosomes [I, R = e.g. OEt, ONa, 4-(2-hydroxyethyl)-1- piperazinyl, NHOH, or NHNH2; R1 = e.g. Q with n = 0 or 1, EtO, Me2CHO, 3-Me2NC6H4O, 4-AcNH-C6H4O, or PhO] or their hydrochlorides or maleates were prepared and used as antiallergics, especially in the treatment of asthma. Thus, reaction of the phenols II with (EtO2C)2 gave I (R = OEt), which optionally were hydrolyzed to give I (R = ONa). Reaction of I (R = Cl) with piperazines gave I(R = 4-substituted 1-piperazinyl) and of I (R = OEt) with NH2OH or N2H4.H2O gave I (R = NHOH or NHNH2, resp.).
IT 52426-46-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52426-46-7 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo-5-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)





RN 42047-74-5 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 5-(3-methylbutoxy)-4-oxo-8-(2-propenyl)- (9CI) (CA INDEX NAME)



L36 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:520460 HCAPLUS Full-text
DOCUMENT NUMBER: 81:120460
TITLE: Organic salts of chromone-2-carboxylic acids
INVENTOR(S): Tronche, Pierre A.
PATENT ASSIGNEE(S): Ferlux
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 3816470	A	19740611	US 1972-256614		19720524	<--
GB 1292826	A	19721011	GB 1969-1292826		19691103	<--
BE 743358	A	19700618	BE 1969-743358		19691218	<--
PRIORITY APPLN. INFO.:			US 1968-780223	A2	19681129	
			FR 1968-179086	A	19681219	
			US 1969-878896	A3	19691121	

OTHER SOURCE(S): MARPAT 81:120460
GI For diagram(s), see printed CA Issue.
AB Chromonecarboxylic acid derivs. I [R = OH.NHEt2, R1 = H, 6-Cl, 7-Me; R = OH.NHMe2, OH.NHBu2, OH.NH2CH2CH2Ph, OH.NH2CH2Ph, OH.morpholine, OH.piperidine, OH.N-methylpiperazine, OH.cyclohexylisopropylamine, OH.2-aminopyridine, OH.papaverino, NHC6H4CO2H, NHC6H3(OH)CO2H-3,4, 2-pyridylamino, NHC6H4OH-p, NHNHPh, piperazinoethoxy, 2-carbamoylcyclohexyloxy, R1 = H] were prepared and showed vitamin P activity. Thus, o-HOC6H4COMe was treated with (EtO2C)2 and NaOMe to give o-HOC6H4COCH2COCO2Et, which was dehydrated to I (R = OH, R1 = H) and treated with NHEt2. In the trypan blue test 40 mg/kg orally in rats I (R = OH.NHEt2, R1 = H) increased the time required for blue spots to appear by 88-109%. The compound was also analgesic in the light beam test at 400-800 mg/kg orally in mice. Its oral LD50 in mice was >5 g/kg.
IT 5112-47-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with p-aminophenol)
RN 5112-47-0 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA

L36 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:95623 HCAPLUS Full-text
DOCUMENT NUMBER: 68:95623
TITLE: Compounds related to 2,4-dichlorophenoxyacetic acid and its derivatives
AUTHOR(S): Barrio, Jorge R.
CORPORATE SOURCE: Univ. Buenos Aires, Buenos Aires, Argent.
SOURCE: Journal of Medicinal Chemistry (1968), 11(2), 374-5
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 68:95623
GI For diagram(s), see printed CA Issue.
AB 2-Carboxy-6,8-dichloro-γ-chromone (I) and its esters and amides were prepared The Fries rearrangement of 2,4-dichlorophenyl acetate gave 3,5-dichloro-2-hydroxyacetophenone, which was treated with di-Et oxalate and NaOEt and then with HOAc-HCl to give I. None of the compds. showed any phytohormonal activity.
IT 17892-56-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17892-56-7 HCAPLUS
CN 4H-1-Benzopyran-2-carbonyl chloride, 6,8-dichloro-4-oxo- (8CI) (CA INDEX NAME)



=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	63.80	541.44
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.25	-24.75

FILE 'STNGUIDE' ENTERED AT 19:00:52 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.02	542.46
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-24.75

FILE 'REGISTRY' ENTERED AT 19:10:49 ON 19 DEC 2006

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346xi.str



chain nodes :
1 2 3 4 6
chain bonds :
1-2 2-3 2-6 3-4
exact/norm bonds :
1-2 2-3 2-6 3-4

G1:Hy,Ph,o-C6H4,m-C6H4,p-C6H4,PhO,n-Bu,i-Bu,s-Bu,t-Bu

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 6:CLASS

L37 STRUCTURE UPLOADED

=> d l37
L37 HAS NO ANSWERS
L37 STR



G1 Hy,Ph,o-C6H4,m-C6H4,p-C6H4,PhO,n-Bu,i-Bu,s-Bu,t-Bu

Structure attributes must be viewed using STN Express query preparation.

=> s l37 sss sam
SAMPLE SEARCH INITIATED 19:11:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3650 TO ITERATE

 54.8% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 69377 TO 76623
PROJECTED ANSWERS: 3953 TO 5829

L38 50 SEA SSS SAM L37

=> d l38

L38 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2006 ACS on STN
RN 910547-45-4 REGISTRY
ED Entered STN: 17 Oct 2006
CN Benzenecarboximidamide, 4,4'-(2,5-pyridinediyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)
MF C19 H17 N5 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d scan

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4,4'-(2,5-pyridinediyl)bis[N-hydroxy- (9CI)
MF C19 H17 N5 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [4-[(aminoacetyl)amino]-2-[[[4-chloro-2-[[[4-[(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-6-(1-methylethoxy)phenoxy]- (9CI)
MF C28 H31 Cl N6 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,1'-Biphenyl]-4-carboximidamide, 4'-heptyl-N-hydroxy- (9CI)
MF C20 H26 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, N-hydroxy-4-[3-[4-[2-methyl-5-(1-methylethyl)-4-thiazolyl]phenoxy]propoxy]- (9CI)
MF C23 H27 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3-Pyridinecarboxamide, N-[5-ethyl-4-[4-[[5-[4-[(hydroxyamino)iminomethyl]phenoxy]pentyl]oxy]phenyl]-2-thiazolyl]- (9CI)
MF C29 H31 N5 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-(2-amino-4-thiazolyl)phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C21 H24 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-(2-ethyl-4-thiazolyl)phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C23 H27 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Thieno[2,3-c]pyridine-2-carboxamidamide, 4-([1,1'-biphenyl]-4-ylamino)-N-hydroxy- (9CI)
MF C20 H16 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-1,2,4-Triazole-1-acetamide, α-ethoxy-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-phenyl- (9CI)
MF C20 H22 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Indole-7-carboximidamide, N-hydroxy-3-[[4-(1-isoquinolinyl)-1-piperazinyl]oxoacetyl]-4-methoxy- (9CI)
MF C25 H24 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[[(5S)-3-[4-[4-[6-[4-[(Z)-amino(hydroxyimino)methyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
MF C29 H33 F N6 O5
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Piperidinecarboximidamide, 4-[[(3,5-dimethyl-2-pyridinyl)methyl][(3-phenyl-2-pyridinyl)methyl]amino]-N-hydroxy- (9CI)
MF C26 H32 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridinium, 3-[(hydroxyamino)iminomethyl]-1-[[2-[[(4-

methoxyphenyl)methoxy]carbonyl]-8-oxo-7-[[[(triphenylmethoxy)imino][2-[(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, [6R-[6α,7β(Z)]]- (9CI)
MF C65 H55 N8 O7 S2
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [[(1R)-1-(cyclohexylmethyl)-2-[(2S)-2,5-dihydro-2-[[[[4-[(hydroxyamino)iminomethyl]-2-thiazolyl]methyl]amino]carbonyl]-1H-pyrrol-1-yl]-2-oxoethyl]imino]-, ethyl ester (9CI)
MF C23 H32 N6 O5 S
CI COM

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Indole-3-carboximidamide, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-N-hydroxy- (9CI)
MF C18 H18 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI)
MF C13 H18 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.78	545.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-24.75

FILE 'STNGUIDE' ENTERED AT 19:11:59 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	545.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-24.75

FILE 'REGISTRY' ENTERED AT 19:15:58 ON 19 DEC 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\346xii.str



chain nodes :
1 2 3 4 6
chain bonds :
1-2 2-3 2-6 3-4
exact/norm bonds :
1-2 2-3 2-6 3-4

G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Hy

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 6:CLASS

L39 STRUCTURE UPLOADED

=> d l39
L39 HAS NO ANSWERS
L39 STR



G1 Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l39 sss sam
SAMPLE SEARCH INITIATED 19:16:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3650 TO ITERATE

 54.8% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS: 69377 TO 76623
PROJECTED ANSWERS: 3953 TO 5829

L40 50 SEA SSS SAM L39

=> d scan

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-[5-(2-chloroethyl)-2-(dimethylamino)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C25 H31 Cl N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Thieno[2,3-c]pyridine-2-carboximidamide, 4-([1,1'-biphenyl]-4-ylamino)-N-hydroxy- (9CI)
MF C20 H16 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-(aminomethyl)-N-hydroxy-, bis(trifluoroacetate) (salt) (9CI)
MF C8 H11 N3 O . 2 C2 H F3 O2

CM 1



CM 2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, N-hydroxy-2-(8-phenyl-1H-imidazo[4,5-c]quinolin-1-

yl)- (9CI)
MF C23 H17 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [2-[[[4-chloro-2-[[[4-[(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-4-[[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-6-(1-methylethoxy)phenoxy]-, 1,1-dimethylethyl ester (9CI)
MF C37 H47 Cl N6 O9



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-(2-amino-4-thiazolyl)phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C21 H24 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [2-chloro-4-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester (9CI)
MF C21 H20 Cl N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridinium, 2-[amino(hydroxyimino)methyl]-1-methyl-, (Z)- (9CI)
MF C7 H10 N3 O
CI COM



L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4,4'-[1,7-heptanediylbis(oxy)]bis[N-hydroxy- (9CI)
MF C21 H28 N4 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, N-hydroxy-4-[3-[4-[2-methyl-5-(1-methylethyl)-4-thiazolyl]phenoxy]propoxy]- (9CI)
MF C23 H27 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzeneacetic acid, 3,5-diethoxy-α-[[4-[(hydroxyamino)iminomethyl]phenyl]amino]-, methyl ester (9CI)
MF C20 H25 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 3-[[(2-amino-4-phenyl-1H-imidazol-1-yl)imino]methyl]-N-hydroxy- (9CI)
MF C17 H16 N6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Indole-3-carboximidamide, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-N-hydroxy- (9CI)
MF C18 H18 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [4-[(aminoacetyl)amino]-2-[[[4-chloro-2-[[[4-[(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-6-(1-methylethoxy)phenoxy]- (9CI)
MF C28 H31 Cl N6 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, N-hydroxy-4-[[5-[4-[5-(methoxymethyl)-2-methyl-4-thiazolyl]phenoxy]pentyl]oxy]- (9CI)
MF C24 H29 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-(1,3-dioxolan-2-yl)-N-hydroxy- (9CI)
MF C10 H12 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridinium, 3-[(hydroxyamino)iminomethyl]-1-[[2-[[(4-methoxyphenyl)methoxy]carbonyl]-8-oxo-7-[[[(triphenylmethoxy)imino][2-[(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, [6R-[6α,7β(Z)]]- (9CI)
MF C65 H55 N8 O7 S2
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN β-D-Psicopyranose, 3-C-[(hydroxyamino)iminomethyl]-1,2:4,5-bis-O-(1-methylethylidene)-, 3-benzoate (9CI)
MF C20 H26 N2 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, N-hydroxy-4-[[2-[[4-[2-methyl-5-(1-methylethyl)-4-thiazolyl]phenoxy]methyl]phenyl]methoxy]- (9CI)
MF C28 H29 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, N-hydroxy-4-[[5-[4-(2-methyl-4-thiazolyl)phenoxy]pentyl]oxy]- (9CI)
MF C22 H25 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[[(5S)-3-[4-[4-[6-[4-[(Z)-amino(hydroxyimino)methyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)
MF C29 H33 F N6 O5
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3-Pyridazinecarboxylic acid, 4-amino-1,6-dihydro-5-[(hydroxyamino)iminomethyl]-1-(4-methoxyphenyl)-6-oxo-, ethyl ester (9CI)
MF C15 H17 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [4-[(aminoacetyl)amino]-2-[[[4-chloro-2-[[[4-[(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-6-(1-methylethoxy)phenoxy]-, ethyl ester (9CI)
MF C30 H35 Cl N6 O7
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-[5-ethyl-2-(propylamino)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C26 H34 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-1,2,4-Triazole-1-acetamide, α-ethoxy-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-phenyl- (9CI)
MF C20 H22 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridinium, 1,1'-(1,3-propanediyl)bis[4-[(hydroxyamino)iminomethyl]- (9CI)
MF C15 H20 N6 O2
CI COM



L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Butenamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-fluoro-3-[3-[(hydroxyamino)iminomethyl]phenyl]-, (2E)- (9CI)
MF C23 H20 F2 N4 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 3-[[4-(2-fluoroethyl)-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]oxy]-N-hydroxy- (9CI)
MF C16 H15 F N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-(2-ethyl-4-thiazolyl)phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C23 H27 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3-Pyridinecarboximidamide, 2-chloro-N-hydroxy-6-(trifluoromethyl)- (9CI)
MF C7 H5 Cl F3 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzeneacetamide, α-(cyclopentylmethyl)-N-[5-[(hydroxyamino)iminomethyl]pyrazinyl]-4-(methylsulfonyl)-, (αR)-(9CI)
MF C20 H25 N5 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN INDEX NAME NOT YET ASSIGNED

MF C4 H6 N6 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3-Pyridinecarboxamide, N-[5-ethyl-4-[4-[[5-[4-[(hydroxyamino)iminomethyl]phenoxy]pentyl]oxy]phenyl]-2-thiazolyl]- (9CI)
MF C29 H31 N5 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 6-Benzofurancarboximidamide, N-hydroxy-2-[4-[(hydroxyamino)iminomethyl]phenyl]- (9CI)
MF C16 H14 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl][(2E)-3-[3-[(hydroxyamino)iminomethyl]phenyl]-2-propenyl]amino]sulfonyl]-, ethyl ester, hydrochloride (2:5) (9CI)
MF C26 H35 N5 O5 S . 5/2 Cl H

Double bond geometry as shown.



●5/2 HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI)
MF C13 H18 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,1'-Biphenyl]-4-carboximidamide, 4'-heptyl-N-hydroxy- (9CI)
MF C20 H26 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboxamidamide, 4-[[5-[4-[5-butyl-2-(3-pyridinyl)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C30 H34 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboxamidamide, 3-[(2,3-dihydro-5,5-dioxido-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)oxy]-N-hydroxy- (9CI)
MF C17 H16 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetic acid, [[(1R)-1-(cyclohexylmethyl)-2-[(2S)-2,5-dihydro-2-[[[[4-[(hydroxyamino)iminomethyl]-2-thiazolyl]methyl]amino]carbonyl]-1H-pyrrol-1-yl]-2-oxoethyl]imino]-, ethyl ester (9CI)
MF C23 H32 N6 O5 S
CI COM

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4,4'-(2,5-pyridinediyl)bis[N-hydroxy- (9CI)
MF C19 H17 N5 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-[5-cyclopentyl-2-(propylamino)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C29 H38 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-1,4-Benzoxazine-2-carboxylic acid, 4-ethyl-3,4-dihydro-7-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-2-methyl-3-oxo-, ethyl ester (9CI)
MF C22 H24 N4 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Piperidinecarboximidamide, 4-[[(3,5-dimethyl-2-pyridinyl)methyl][(3-phenyl-2-pyridinyl)methyl]amino]-N-hydroxy- (9CI)
MF C26 H32 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3-Pyridinecarboximidamide, N-hydroxy-6-[5-[3-[(hydroxyamino)iminomethyl]phenyl]-2-furanyl]- (9CI)
MF C17 H15 N5 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-[6-[(hydroxyamino)iminomethyl]-3-pyridinyl]-5-methyl-2-nitro- (9CI)
MF C14 H13 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenecarboximidamide, 4-[[5-[4-[5-(cyclopentylmethyl)-2-ethyl-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)
MF C29 H37 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Indole-7-carboximidamide, N-hydroxy-3-[[4-(1-isoquinolinyl)-1-piperazinyl]oxoacetyl]-4-methoxy- (9CI)
MF C25 H24 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Furancarboximidamide, 5-(2-aminophenyl)-N-hydroxy- (9CI)
MF C11 H11 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Thiophenecarboximidamide, 3-bromo-N-hydroxy- (9CI)
MF C5 H5 Br N2 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.88	546.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-24.75

FILE 'STNGUIDE' ENTERED AT 19:17:00 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.20	547.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-24.75